 
 
Official Title: ILLUMINATE- A: A Phase 3 Randomized, Double -blind, Placebo- Controlled  Study with 
an Extended Dosing Period to Evaluate the Efficacy and Safety of Lumasiran in Children and 
Adults with Primary Hyperoxaluria Type 1  
 
Study ID: [REMOVED]  
 
Document Date:   Protocol Amendment 3, 06 May 2020 
 
Clinical Study Protocol ALN -GO1 -003 lumasiran  
Amendment  3, 06 May  2020 
Alnylam Pharmaceuticals  Confidential  3 INVESTIGATOR’S AGREE MENT  
I have read the ALN -GO1 -003 protocol and agree to conduct the study in accordance with the 
protocol and all applicable regulations.  I agree to ensure that Financial Disclosure Statements 
will be completed by me (includi ng, if applicable, my spouse [or legal partner] and dependent 
children), my subinvestigators (including, if applicable, their spouses [or legal partners] and 
dependent children) at the start of the study and for up to 1 year after the study is completed, i f 
there are changes that affect my financial disclosure status.   I agree to maintain the 
confidentiality of all information received or developed in connection with this protocol.   
 
             
Printed Name of Investigator  
 
             
Signature of Inves tigator  
 
       
Date  
Clinical Study Protocol ALN -GO1 -003 lumasiran  
Amendment  3, 06 May  2020 
Alnylam Pharmaceuticals  Confidential  6 month blinded treatment extension period and an open -label extension period of up to 51  months.  A 
schematic of the study design is shown in Figure  1. 
Number of Planned Patients  
The planned enrollment for this study is 30  patients.  
Diagnosis and Main Eligibility Criteria  
This study will include adults and children (≥6 years of age) with a documented diagnosis of PH1 based 
on urinary oxalate excretion ≥0.7 0 mmol/24h/1.73m2 and confirmed alanine glyoxylate aminotransferase 
(AGXT ) mutation s, and  eGFR ≥30 mL/min/1.73m2 at screening.  
Study Drug, Dose, and Mode of Administration  
Lumasiran (ALN -GO1) is an investigational agent comprised of a synthetic, small interfering RNA 
(siRNA) (drug substance ALN -65585) covalently linked to a triantennary N-acetylgalactosamine 
(GalNAc ) ligand, designed to target liver hydroxyacid oxidase 1 ( HAO1) mRNA, blocking production of 
glycolate oxidase (GO) and hence red ucing hepatic oxalate production . 
Lumasiran will be administered at a dose of  3.0 mg/kg as a subcutaneous ( SC) injection.  See Figure  1 
for the dose schedule.  
Reference Treatment, Dose, and Mode of Administration  
The control drug for this study will be a placebo (sodium chloride 0.9% w/v for SC administration).   See 
Figure  1 for the dose schedule.  
Duration of Treatment and Study  
The duration of treatment with study drug is up to 5 years, including a 6 -month double -blind treatment 
period followed by a 3 -month blinded treatment extension period, and up to a 51 -month open -label 
extension period.  
The estimated total time on study, inclusive of screening, for each patient is up to 62 months, including up 
to 2 months of screeni ng followed by up to 60 months of treatment.  
Figure  1: Study Design  
 
Abbreviations:  q3M= once every 3 months; qM= once monthly ; qMx3= once monthly for 3 consecutive months  
*  Patients randomized to lumasiran will also  receive 2 qM doses of placebo during the 3 -month blinded treatment 
extension p eriod . 

Clinical Study Protocol ALN -GO1 -003 lumasiran  
Amendment  3, 06 May  2020 
Alnylam Pharmaceuticals  Confidential  14 • See Section  4.3.1  for instruction s for patients who discontinue study drug.  
• In situations where a study visit is unable to be completed (either at the site or offsite by a healthcare professional), the  Investigator (or delegate) will 
verbally contact the patient within the study visit win dow to assess concomitant medications, renal stone events, adverse events,  and healthcare 
utilization . 
• Gray -shaded column indicates the visit where assessments span 2  days.  
Table  3: Pharmacokinetic and ECG Assessment  Time Points : All Sites except East Asian Sites  
Study Month/ Study Day  Sampling Time  
(hh:mm)  Blood PK Sample  ECG  
Screening  Any time during visit   Xa 
Month 0  
(Day 1)  Predose  X Xb 
04:00 (±1 hour)  X Xb 
24:00 (±2 hours)  X  
Month 3  
(Day  85± 4 days)  Predose  X Xa 
04:00 (±1 hour)  X  
Month 6 (Day  169±7  days)  Predose  X Xb 
04:00 (±1 hour)  X Xb 
24:00 (±2 hours)  X  
Month 9 (Day  253±4  days)  Predose  X Xa 
04:00 (±1 hour)  X  
Month 12 (Day  337± 28 days)  Predose  X Xa 
04:00 (±1 hour)  X  
24:00 (±2 hours)  X  
Months 24, 36, 48, 60 (see Table  2) Predose   Xa 
Abbreviations:  ECG=electrocardiogram; hh:mm=hour:minute;  PK=pharmacokinetics  
Notes:  
• Predose samples are collected on the day of dosing.  
• The hour ( ±range) indicate sample collection timing relative to dosing.  Precise PK sample times (hour and minute)  are recorded.  See Section  7.2.7  for 
additional information on PK as sessments.  
Clinical Study Protocol ALN -GO1 -003 lumasiran  
Amendment  3, 06 May  2020 
Alnylam Pharmaceuticals  Confidential  15 • Patients should be supine for at least 10  minutes before each ECG is obtained. See Section  6.5.4  for additional information on ECG assessments.  
• Blood samples for PK assessment may be collected at 24  hours postdose as feasible during periods of time when the COVID -19 pandemic impedes the 
ability of patients to travel to the study site and the healthcare professionals to go to the patients’ homes.     
a For Screening, Month  3, Month  9, Month  12 and annual visits (Month  24, Month  36, Month  48, Month  60), singlicate ECGs are performed using a local ECG 
machine.   During periods of time when the COVID -19 pandemic impedes the ability of patients to travel to the study site,  ECG assessments may be completed 
up to 7  months after the intended timepoint for visits at Month  12 and later.  
b For Month 0 (Day 1) and Month 6, triplicate ECGs are performed predose and postdose timepoints using a central machine and central reads.   Triplicate ECG 
readings occur approximately 5 minutes apart.   
Table  4: Pharmacokinetic an d Electrocardiogram  Assessment Time Points : East Asian Sites  
Study Month  
(Study Day)  Sampling Time  
(hh:mm)  Blood PK Sample  ECG  
Screening  Any time during visit   Xa 
Month 0  
(Day 1)  Predose  X Xb 
00:30 (±10 min)  X  
02:00 (±20 min)  X  
04:00 (±20 min) X Xb 
06:00 (±20 min)  X  
08:00 (±20 min)  X  
24:00 (±2 hours)  X Xb 
Month 3  
(Day 85±4 days)  Predose  X Xa 
04:00 (±1 hour)  X  
Month 6 (Day  169±7  days)  Predose  X Xb 
00:30 (±10 min)  X  
02:00 (±20 min)  X  
04:00 (±20 min)  X Xb 
06:00 (±20 min) X  
Clinical Study Protocol ALN -GO1 -003 lumasiran  
Amendment  3, 06 May  2020 
Alnylam Pharmaceuticals  Confidential  16 Study Month  
(Study Day)  Sampling Time  
(hh:mm)  Blood PK Sample  ECG  
08:00 (±20 min)  X  
24:00 (±2 hours)  X Xb 
Month 9 (Day  253±4  days)  Predose  X Xa 
04:00 (±1 hour)  X  
Month 12 (Day  337)  Predose  X Xb 
 00:30 (±10 min)  X  
 02:00 (±20 min)  X  
 04:00 (±1 hour)  X Xb 
 06:00 (±20 min)  X  
 08:00 (±20 min)  X  
 24:00 (±2 hours)  X Xb 
Months 24, 36, 48, 60 (see Table  2) Predose   Xa 
Abbreviations:  ECG=electrocardiogram; hh:mm=hour:minute; PK=pharmacokinetics  
Notes:  
• East Asian includes sites in China, Korea, Japan, Taiwan, and Hong Kong.  
• Predose samples are collected on the day of dosing.  
• The hour ( ±range) indicate sample collection timing relative to dosing.   Precise PK sample times (hour and minute)  are recorded .  See Section  7.2.7  for 
additional information on PK assessments.   
• Patients should be supine for at least 10  minutes before each ECG is obt ained . See Section  6.5.4  for additional information on ECG assessments.  
a For Screening , Month 3, Month 9,  and annual visits (Month 24, Month 36, Month 48, Month 60), singlicate ECGs are performed using a local ECG machine.   
b For Month 0 (Day 1) , Month  6, and Month  12 triplicate ECGs are performed predose and postdose timepoints using a central machine and c entral reads.   
Triplicate ECG readings occur approximately 5 minutes apart.  
 
Clinical Study Protocol ALN -GO1 -003 lumasiran  
Amendment  3, 06 May  2020 
Alnylam Pharmaceuticals  Confidential  17 Table  5: Urine Pharmacokinetic Assessment Time Points : East Asian Sites  
Study Day  Sampling Time  
(hh:mm)  Pooled Urine  
PK Sample  
Month 0  
(Day 1)  Predose  X 
0-6 hours (±30 min)  X 
6-12 hours (±30 min)  X 
12-24 hours (±2 hours)  X 
Month 6  
(Day 169 ±7  days)  Predose  X 
0-6 hours (±30 min)  X 
6-12 hours (±30 min)  X 
12-24 hours (±2 hours)  X 
 
 
Month 12 (Day  337±7  days)  Predose  X 
0-6 hours (±30 min)  X 
6-12 hours (±30 min)  X 
12-24 hours (±2 hours)  X 
Abbreviations:  hh:mm=hour:minute; PK=pharmacokinetics  
Notes:  
• East Asian includes sites in China, Korea, Japan, Taiwan, and Hong Kong.  
• The hour ( ±range) indicate sample collection timing relative to dosing.  Precise PK sample times (hour and minute) are 
recorded.  See Section  6.4.1  and Section  7.2.7  for additional information on PK assessments.  
• All predose samples are spot urine samples; postdose urine samples are pooled sample s.
Clinical Study Protocol ALN -GO1 -003 lumasiran  
Amendment  3, 06 May  2020 
Alnylam Pharmaceuticals  Confidential  18 TABLE OF CONTENTS  
SPONSOR PROTOCOL APP ROVAL  ................................ ................................ ........................... 2 
INVESTIGATOR’S AGREE MENT  ................................ ................................ ............................... 3 
PROTOCOL S YNOPSIS  ................................ ................................ ................................ ................ 4 
TABLE OF CONTENTS  ................................ ................................ ................................ ............... 18 
LIST OF TABLES  ................................ ................................ ................................ ......................... 22 
LIST OF FIGURES  ................................ ................................ ................................ ....................... 22 
LIST OF ABBREVIATION S AND DEFINITIONS OF  TERMS  ................................ ................ 23 
1. INTRODUCTION  ................................ ................................ ................................ ......26 
1.1. Disease Overview  ................................ ................................ ................................ .......26 
1.2. Lumasiran (ALN -GO1)  ................................ ................................ .............................. 27 
1.2.1.  Summary of Nonclinical Data with Lumasiran  ................................ .......................... 27 
1.2.2.  Summary of Clinical Data with Lumasiran  ................................ ................................ 28 
1.3. Study Design Rationale  ................................ ................................ .............................. 28 
1.4. Dose Rationale  ................................ ................................ ................................ ............ 29 
1.5. Benefit -Risk Assessment  ................................ ................................ ............................ 30 
2. OBJECTIVES AND ENDPO INTS  ................................ ................................ ............ 31 
3. INVESTIGATIONAL PLAN  ................................ ................................ ..................... 32 
3.1. Summa ry of Study Design  ................................ ................................ .......................... 32 
3.2. Duration of Treatment  ................................ ................................ ................................ 34 
3.3. Duration of Study  ................................ ................................ ................................ .......34 
3.3.1.  Definition of End of Study for an Individual Patient  ................................ ................. 34 
3.4. Number of Planned Patients  ................................ ................................ ....................... 34 
3.5. Method of Assigning Patients to Treatment Groups  ................................ .................. 34 
3.6. Blinding  ................................ ................................ ................................ ...................... 34 
3.6.1.  Emergency Unb linding  ................................ ................................ ............................... 35 
3.7. Data Monitoring Committee  ................................ ................................ ....................... 36 
4. SELECTION AND WITHDR AWAL OF PATIENTS  ................................ .............. 36 
4.1. Inclusion Criteria  ................................ ................................ ................................ ........ 36 
4.2. Exclusion Criteria  ................................ ................................ ................................ .......36 
4.3. Removal from Therapy or Assessment ................................ ................................ .......37 
Clinical Study Protocol ALN -GO1 -003 lumasiran  
Amendment  3, 06 May  2020 
Alnylam Pharmaceuticals  Confidential  19 4.3.1.  Discontinuation of Study Drug  ................................ ................................ ................... 38 
4.3.2.  Stopping a Patient's Study Participation  ................................ ................................ .....38 
4.3.3.  Replacement of Study Patients  ................................ ................................ ................... 39 
4.3.4.  Lost to Follow -Up................................ ................................ ................................ .......39 
5. TREATMENTS AND OTHER  REQUIREMENTS  ................................ .................. 40 
5.1. Treatments Administered  ................................ ................................ ............................ 40 
5.2. Study Drug  ................................ ................................ ................................ .................. 40 
5.2.1.  Description  ................................ ................................ ................................ .................. 40 
5.2.2.  Dose and Administration  ................................ ................................ ............................ 40 
5.2.3.  Dose Modifications  ................................ ................................ ................................ .....41 
5.2.3.1.  LFT Criteria for Withholding, Monitoring and Stopping Study Drug Dosing ........... 41 
5.2.4.  Preparation, Handling, and Storage  ................................ ................................ ............ 43 
5.2.5.  Packaging and Labeling  ................................ ................................ .............................. 44 
5.2.6. Accountability  ................................ ................................ ................................ ............. 44 
5.3. Concomitant Medications  ................................ ................................ ........................... 44 
5.4. Treatment Compliance  ................................ ................................ ................................ 45 
5.5. Other Requirements  ................................ ................................ ................................ ....45 
5.5.1.  Contraception  ................................ ................................ ................................ .............. 45 
5.5.2.  Alcohol Restrictions  ................................ ................................ ................................ ...46 
5.5.3.  Dietary Restrictions  ................................ ................................ ................................ ....46 
6. STUDY ASSESSMENTS  ................................ ................................ .......................... 46 
6.1. Screening Assessments  ................................ ................................ ............................... 46 
6.1.1.  Retesting  ................................ ................................ ................................ ..................... 47 
6.1.2.  Rescreening  ................................ ................................ ................................ ................. 47 
6.2. Efficacy Assessments  ................................ ................................ ................................ .47 
6.3. Pharmacodynamic and Renal Assessments  ................................ ................................ 47 
6.3.1.  24-hour Urine Collections to determine Urinary Oxalate Excretion  .......................... 47 
6.3.1.1.  Validity Criteria for 24 -hour Urine Collections  ................................ ......................... 49 
6.3.1.2.  Urinary Oxalate:Creatinin e Ratio  ................................ ................................ ............... 49 
6.3.2.  Estimated Glomerular Filtration Rate  ................................ ................................ ......... 49 
6.3.3.  Renal Stone Events  ................................ ................................ ................................ .....49 
6.3.4.  Sample Analysis  ................................ ................................ ................................ ......... 49 
6.4. Pharmacokinetic Assessments  ................................ ................................ .................... 50 
Clinical Study Protocol ALN -GO1 -003 lumasiran  
Amendment  3, 06 May  2020 
Alnylam Pharmaceuticals  Confidential  20 6.4.1.  Pharmacokinetic Assessments in Patients at East Asian Study Centers  ..................... 50 
6.5. Safety Assessments  ................................ ................................ ................................ .....50 
6.5.1.  Vital Signs  ................................ ................................ ................................ .................. 50 
6.5.2.  Weight and Height  ................................ ................................ ................................ ......51 
6.5.3.  Physical Examination  ................................ ................................ ................................ .51 
6.5.4.  Electrocardiogram  ................................ ................................ ................................ .......51 
6.5.5.  Renal Ultrasound  ................................ ................................ ................................ ........ 51 
6.5.6.  Clinical Laboratory Assessments  ................................ ................................ ............... 52 
6.5.6.1.  Immunogenicity  ................................ ................................ ................................ .......... 53 
6.5.6.2.  Pregnancy Testing  ................................ ................................ ................................ ......54 
6.5.6. 3. Additional Liver Function Assessments  ................................ ................................ .....54 
6.5.6.4.  Maximum Blood Volume  ................................ ................................ ........................... 55 
6.5.7.  Adverse Events  ................................ ................................ ................................ ........... 56 
6.5.7.1.  Definitions  ................................ ................................ ................................ .................. 56 
6.5.7.2.  Eliciting and Recording Adverse Events  ................................ ................................ ....57 
6.5.7.3.  Reporting Adverse Events of Clinical Interest to Sponsor/Designee  ......................... 58 
6.5.7.4.  Serious Adverse Events Require Immediate Reporting to Sponsor/Designee  ........... 58 
6.5.7.5.  Sponsor Safety Reporting to Regulatory Authorities  ................................ ................. 59 
6.5.7.6.  Serious Adverse  Event Notification to the Institutional Review 
Board/Independent Ethics Committee  ................................ ................................ ........ 59 
6.5.7.7.  Pregnancy Reporting  ................................ ................................ ................................ ..59 
6.5.7.8.  Overdose Reporting  ................................ ................................ ................................ ....59 
6.5.8.  COVID -19 Data Collection  ................................ ................................ ........................ 60 
6.6. Biomarkers, DNA Genotyping, and Biospecimen Repository  ................................ ...60 
6.7. Quality of Life (QOL)  ................................ ................................ ................................ 60 
6.8. Patient and Caregiver Experience Surveys  ................................ ................................ .61 
6.9. Patient and Caregiver Impact Questionnaire  ................................ .............................. 61 
6.10.  Healthcare Resource Utilization  ................................ ................................ ................. 62 
7. STATISTICS  ................................ ................................ ................................ .............. 62 
7.1. Determination of Sample Size  ................................ ................................ .................... 62 
7.2. Statistical Methodology  ................................ ................................ .............................. 62 
7.2.1.  Populations to be Analyzed  ................................ ................................ ........................ 62 
7.2.2.  Examination of Subgroups  ................................ ................................ ......................... 63 
Clinical Study Protocol ALN -GO1 -003 lumasiran  
Amendment  3, 06 May  2020 
Alnylam Pharmaceuticals  Confidential  21 7.2.3.  Handling of Missing Data  ................................ ................................ ........................... 63 
7.2.4.  Baseline Evaluations  ................................ ................................ ................................ ...63 
7.2.5.  Efficacy Analyses  ................................ ................................ ................................ .......63 
7.2.5.1.  Primary Endpoint  ................................ ................................ ................................ ........ 63 
7.2.5.2.  Secondary Endpoints  ................................ ................................ ................................ ..64 
7.2.5.3.  Exploratory Endpoints  ................................ ................................ ................................ 64 
7.2.6.  Pharmacodynamic Analysis ................................ ................................ ........................ 64 
7.2.7. Pharmacokinetic Analysis  ................................ ................................ .......................... 64 
7.2.8.  Safety Analyses  ................................ ................................ ................................ .......... 65 
7.2.9.  Immunogenicity Analyses  ................................ ................................ .......................... 65 
7.2.10.  Other Analyses  ................................ ................................ ................................ ............ 65 
7.2.11.  Interim Analysis  ................................ ................................ ................................ .......... 65 
7.2.12.  Optional Additional Research  ................................ ................................ ..................... 65 
8. STUDY ADMINISTRATION  ................................ ................................ ................... 65 
8.1. Ethic al and Regulatory Considerations  ................................ ................................ ......65 
8.1.1.  Informed Consent  ................................ ................................ ................................ .......66 
8.1.2.  Ethical Review  ................................ ................................ ................................ ............ 66 
8.1.3.  Serio us Breach of Protocol  ................................ ................................ ......................... 67 
8.1.4.  Study Documentation, Confidentiality, and Records Retention  ................................ .67 
8.1.5.  End of Study  ................................ ................................ ................................ ............... 67 
8.1.6.  Termination of the Clinical Study or Site Closure  ................................ ..................... 67 
8.2. Data Quality Control and Quality Assurance  ................................ ............................. 68 
8.2.1.  Data Handling  ................................ ................................ ................................ ............. 68 
8.2.2.  Study Monitoring  ................................ ................................ ................................ ........ 68 
8.2.3.  Audits and Inspections  ................................ ................................ ................................ 68 
8.3. Publication Policy  ................................ ................................ ................................ .......69 
9. LIST OF REFERENCES  ................................ ................................ ............................ 70 
10. APPENDICES  ................................ ................................ ................................ ............ 72 
10.1.  Formulae for  Estimated Glomerular Filtration Rate Calculation  ............................... 72 
10.2.  Blood Volume Limits in Pediatric Patients  ................................ ................................ 73 
 
Clinical Study Protocol ALN -GO1 -003 lumasiran  
Amendment  3, 06 May  2020 
Alnylam Pharmaceuticals  Confidential  22 LIST OF TABLES  
Table  1: Schedule of Assessments – 6-Month Double -Blind Treatment Period and 
Blinded Treatment Extension (Screening thr ough Month  9 Assessments)  .................. 7 
Table  2: Schedule of Assessments – Open Label Extension Period (After Month 9 
through Year 5)  ................................ ................................ ................................ ........... 11 
Table  3: Pharmacokinetic and ECG Assessment Time Points: All Sites except East 
Asian Sites  ................................ ................................ ................................ .................. 14 
Table  4: Pharmacokinetic and Electrocardiogram Assessment Time Points: East 
Asian Sites  ................................ ................................ ................................ .................. 15 
Table  5: Urine Pharmacokinetic Assessment Time Points: East Asian Sites  ........................... 17 
Table  6: Monitoring and Dosing Rules for Asymptomatic Patients with Confirmed 
Isolated Elevations of ALT and/or AST >3× ULN, with No Alternative 
Cause Identifie d ................................ ................................ ................................ .......... 43 
Table  7: 24-hour Urine Collection Procedure by Study Visit ................................ ................... 48 
Table  8: Clinical Laboratory Assessments  ................................ ................................ ............... 53 
Table  9: Hepatic Assessments in Patients Who Experience Elevated Transaminases  ............. 55 
Table  10: Maximum Allowable Total Blood Volume Collection Chart  ................................ ....73 
 
LIST OF FIGURES  
Figure  1: Study Design  ................................ ................................ ................................ ................. 6 
 
Clinical Study Protocol ALN -GO1 -003 lumasiran  
Amendment  3, 06 May  2020 
Alnylam Pharmaceuticals  Confidential  23 LIST OF ABBREVIATION S AND DEFINITIONS OF  TERMS  
Abbreviation  Definition  
ADA  Anti-drug antibody  
AE Adverse event  
AGT  Alanine -glyoxylate aminotransferase  
AGXT  Alanine glyoxylate aminotransferase gene  
ALT  Alanine aminotransferase  
AST  Aspartate aminotransferase  
ATC  Anatomical Therapeutic Chemical Classification System  
AUC  Area under the concentration -time curve  
BSA  Body surface area  
Cmax Maximum plasma concentration  
CFR  Code of Federal Regulation  
CL/F  Apparent clearance  
COVID -19 Coronavirus disease 2019  
DMC  Data Monitoring Committee  
ECG  Electrocardiogram  
eCRF  Electronic case report form  
eGFR  Estimated glomerular filtration rate  
EOS  End of study 
EOT  End of treatment  
ET Early termination  
EQ-5D Euro Quality of Life Health State Profile Questionnaire  
ESRD  End-stage renal disease  
FAS Full analysis set  
GalNAc  N-acetylgalactosamine  
GCP  Good Clinical Practice  
GLP  Good Laboratory Practice  
GO Glycolate oxidase  
HAO1  Hydroxyacid oxidase 1  
HBV  Hepatitis B virus  
HCV  Hepatitis C virus  
HIV Human immunodeficiency virus  
Clinical Study Protocol ALN -GO1 -003 lumasiran  
Amendment  3, 06 May  2020 
Alnylam Pharmaceuticals  Confidential  24 Abbreviation  Definition  
ICF Informed consent form  
ICH International Council on Harmonisation  
IEC Independent Ethics Committee  
IND Investigational New Drug  
INR International normalized ratio  
IRB Institutional Review Board  
IRS Interactive Response System  
ISR Injection site reactions  
KDQOL  Kidney Disease Quality of Life Questionnaire  
LFT Liver function tests  
MAD  Multiple -ascending dose  
MDRD  Modification of diet in renal disease  
MedDRA  Medical Dictionary for Regulatory Activities  
MMRM  Mixed -effect model for repeated measures  
MNAR  Missing not at random  
mRNA  Messenger ribonucleic acid  
OLE  Open -label extension  
PD Pharmacodynamic  
PedsQL  Pediatric Quality of Life Inventory  
PH1 Primary hyperoxaluria type 1  
PK Pharmacokinetic  
PMM  Pattern mixture model  
PP Per protocol  
PT Preferred Term  
q3M  Once every  3 months  
qM Once m onthly   
qMx 3 Once monthly for 3 consecutive months  
SAD  Single -ascending dose  
SAE  Serious adverse event  
SAP Statistical analysis plan  
SC Subcutaneous  
siRNA  Small interfering  RNA  
Clinical Study Protocol ALN -GO1 -003 lumasiran  
Amendment  3, 06 May  2020 
Alnylam Pharmaceuticals  Confidential  25 Abbreviation  Definition  
SOC  System Organ Class  
SUSAR  Suspected unexpected serious adverse reaction  
t½β Elimination half -life 
tmax Time to maximum plasma concentration  
TMF  Trial master file  
ULN  Upper limit of normal  
V/F Apparent volume of distribution  
VAS  Visual analog scale  
WOCBP  Women of child -bearing potential  
WHO  World Health Organization  
 
Clinical Study Protocol ALN -GO1 -003 lumasiran  
Amendment  3, 06 May  2020 
Alnylam Pharmaceuticals  Confidential  26 1. INTRODUCTION  
1.1. Disease Overview  
Primary hyperoxaluria type 1 ( PH1) is a rare autosomal recessive disease characterized by 
excessive oxalate production by the liver and consequent hyperoxaluria.  PH1 is caused by 
mutations in the a lanine glyoxylate aminotransferase ( AGXT ) gene, which encodes the liver 
peroxisomal enzyme alanine -glyoxylate aminotransferase (AGT).  As a consequence of AGT 
deficiency, glyoxylate accumulates  and is oxidized to oxalate in the hepatocyte and ultimately 
transported to the kidneys for excretion.  Oxalate, in the form of its calcium salt, is excreted 
almost entirely by the kidney.  Due to its insolubility, calcium oxalate can crystallize readily in 
the urinary tract.  In PH1, excess urinary oxalate results in  recurrent nephrolithiasis and/or 
nephrocalcinosis, which can lead to pain, infections, progressive kidney disease and failure, 
along with reduced quality of life. [Cochat and Rumsby 2013 ]  As renal function declines, 
elimination of oxalate is further reduced, such that calcium oxalate accumulates in bone, 
vasculature, skin, retina, heart, and nervous system, resulting in severe end -organ 
damage. [Cochat and Rumsby 2013 ]  This devastating condition, systemic oxalosis, arises when 
the estimated glomerular filtr ation rate (eGFR) has declined to below 30 to 45 mL/min /1.73 
m2.[Cochat a nd Rumsby 2013 ]  Without treatment, the disease progresses inexorably, and death 
from end -stage renal disease (ESRD) and/or complications of oxalosis is inevitable. [Cochat and 
Rumsby 2013 ; Harambat 2010 ; van der Hoeven 2012 ]   
Over 150 mutations in AGXT have been described. [Williams 2009 ]  While there  are broad 
genotype –phenotype associations with the underlying causative defect, patients can present with 
very different symptoms, disease course, including timing of an individual’s eGFR decline, and 
treatment response. [Danpure 2014 ; Hoppe 1997 ]  Patients progress  at various rates and an event 
that leads to a cute or chronic worsening, such as an obstructive kidney stone or episode of 
dehydration, can occur at any time.  
The incidence of PH1 is approximately 1 in 120,000 live births, and the prevalence is 1 to 3 per 
million in North America and Europe. [Cochat and Rumsby 2013 ; Hopp 2015 ; Hoppe 2010 ]  The 
disease is more prevalent in areas where consanguineous marriages are common, especially in 
the Middle East and Northern Africa. [Al-Eisa 2004 ; Boualla 2015 ; Frishberg 2005 ; Kamoun and 
Lakhoua 1996 ] 
PH1 often presents as a pediatric disease, but many patients remain undiagnosed for years after 
the initial clinical manifestations of the disease. [Lieske 2005 ; Mandrile 2014 ; van Woerden 
2003 ]  A recently published analysis of 247 patients with PH1 from 206 pedigrees in the Rare 
Kidney Stone Consortium PH Registry demonstrated a median age of first symptoms at 5.2 years 
of age a nd a cumulative renal survival of 76%, 43%, and 12% at 20 years, 40 years, and 60 
years, respectively. [Hopp 2015 ]  Similarly, an analysis of 526 patients with PH1 published by 
the OxalEurope Consortium indicated a median age of disease symptom onset of 3.9 years and a 
median age of diagnosis of 8.1 years.  Overa ll, 43% of all patients diagnosed with PH1 had 
already progressed to ESRD at the time of diagnosis. [Mandrile 2014 ]  The deterioration of renal 
function highlights the importance of investigating potentially disease -modifying interventions 
as soon as possible after diagnosis.  
Clinical Study Protocol ALN -GO1 -003 lumasiran  
Amendment  3, 06 May  2020 
Alnylam Pharmaceuticals  Confidential  27 There are no approved therapies for the treatment of PH1 and the current s tandard of care is 
burdensome to patients and their families.  Disease management is based on supportive 
measures, including high fluid intake and crystallization inhibitors to increase urinary oxalate 
solubility, and treatment of disease complications suc h as urinary tract stones and infections.  A 
minority of patients experience oxalate lowering with therapeutic doses of pyridoxine ( vitamin 
B6).  Dietary modification plays a minor role in treatment since endogenous oxalate production 
far exceeds dietary i ntake.  Patients progressing to, or presenting with ESRD require intense 
kidney dialysis.  Dialysis is not viewed as an effective therapy for PH1, but rather serves as a 
bridge to a liver -kidney transplant or as an alternative to no therapy at all.  Dialys is is often 
inadequate to effectively offload accumulating oxalate , and systemic oxalosis with end organ 
damage may develop despite this burdensome treatment.  Dialysis regimens for PH1 are more 
involved than conventional dialysis, predisposing to increase d risk of complications.  Combined 
liver/kidney transplantation offers potentially curative therapy; but is limited due to restricted 
availability, complications associated with the procedure, ethical considerations in resource -poor 
settings [Cochat and Rumsby 2013 ], and intense  use of health care resources.  
PH1 can progress  to be a serious, severely debilitating disease with significant morbidity and 
mortality and negatively impacts quality of life.   Limited and burdensome management options 
for PH1 outlined above highlight the serious unmet need for a safe and efficacious t reatment for 
patients with this devastating disease.  
1.2. Lumasiran (ALN -GO1)  
Alnylam Pharmaceuticals, Inc. (the Sponsor) is developing lumasiran (ALN -GO1), an 
investigational agent comprised of a synthetic, small interfering RNA (siRNA) (drug substance 
ALN -65585) covalently linked to a triantennary N-acetylgalactosamine ( GalNAc ) ligand, 
designed to target liver hydroxyacid oxidase 1 ( HAO1 ) mRNA, blocking production of glycolate 
oxidase (GO) and hence reducing hepatic oxalate production, which is the underlying cause of 
the morbidity and mortality associated with PH1.  
The proposed indication for lumasiran is the treatment of primary hyperoxaluria t ype 1 (PH1).  
1.2.1.  Summary of Nonclinical Data with Lumasiran  
The pharmacology, safety pharmacology, pharmacokinetics, and  toxicology of lumasiran were 
evaluated in a series of in vitro and in vivo nonclinical studies.  Lumasiran was 
pharmacologically active in rodents and cynomolgus monkeys  (hereafter referred to as 
monkeys) .  Subcutaneous ( SC) administration of lumasiran de monstrated potent, dose -dependent 
pharmacologic activity resulting in reduced hepatic HAO1  mRNA levels with the expected 
increases in glycolate levels in wild -type and diseased animals and subsequent reductions in 
urinary oxalate in diseased animals.  
No lu masiran -related safety pharmacology findings were identified in Good Laboratory Practice 
(GLP) -compliant repeat dose toxicity studies in monkeys.  Lumasiran was well tolerated in both 
the rat and monkey repeat dose toxicology studies and did not result in any dose -limiting effects 
at the highest doses tested.  In vitro and in vivo genetic toxicity studies were all negative at 
(ICH) S2 (R1) limit doses.  Based on this class of drugs and the data to date, a favorable safety 
profile of lumasiran has been demon strated and supports the use of lumasiran in the current 
study.  
Clinical Study Protocol ALN -GO1 -003 lumasiran  
Amendment  3, 06 May  2020 
Alnylam Pharmaceuticals  Confidential  28 A summary of nonclinical studies is included in the current edition of the Investigator’s 
Brochure.  
1.2.2.  Summary of Clinical Data with Lumasiran   
Lumasiran is being  investigated in 2 ongoing clinical studies, Study ALN -GO1 -001 and Study 
ALN -GO1 -002.  
Study ALN -GO1 -001 is a 2 -part ( single -ascending dose [ SAD ] and multiple -ascending dose 
[MAD ]) study designed to evaluate the safety, tolerability, PK, and PD of lumasira n in healthy 
adult subjects and in adult and pediatric patients with PH1.  In the SAD part of the study (Part 
A), healthy adult subjects were randomized to receive one single blind dose of lumasiran (0.3 -6.0 
mg/kg) or placebo (6:2).  In the MAD part of the  study (Part B), patients ≥6 years of age with 
PH1 and eGFR>45 mL/min /1.73 m2 were randomized 3:1 to receive single blind doses of 
lumasiran or placebo at 1 mg/kg monthly for 3 doses, 3 mg/kg monthly for 3 doses or 3 mg/kg 
every 3 months for  2 doses.  Pati ents who initially received placebo transitioned to an open -label 
portion of the study to receive doses of lumasiran.  The primary objective is to evaluate the 
safety and tolerability of subcutaneously administered lumasiran.  Secondary and exploratory 
objectives of the study include the characterization of plasma and urine PK and the evaluation of 
the PD effect, including glycolate and oxalate levels.   
Study ALN -GO1 -002 is a Phase 2 open -label extension study to evaluate the long -term safety , 
PK, and PD  of lumasiran in patients with PH1 who have completed Study ALN -GO1 -001.  
Available safety data indicate that lumasiran has an acceptable safety and tolerability profile 
across all dosing regimens evaluated.  Preliminary data from Study ALN -GO1 -001 demonstrate 
a mean maximal reduction in 24 -hour urinary oxalate of 64% (Cohorts 1 -3) and achievement of 
normal to near -normal levels of urinary oxalate (<0.7 0 mmol/ 24h/1.73 m2) in patients dosed with 
lumasiran  (range: 0.29 to 0.67  mmol/ 24h/1.73 m2).  Furth er information on the chemistry, 
pharmacology, efficacy, and safety of lumasiran is provided in the current edition of the 
Investigator’s Brochure.  
1.3. Study Design Rationale  
Lumasiran is proposed to reduce urinary oxalate production resulting in lower urinary  oxalate 
excretion in patients with relatively intact renal function.  In preclinical models and in patients 
with PH1, SC administration of lumasiran demonstrated potent, dose -dependent pharmacologic 
activity resulting substantial reductions in urinary oxa late.[Liebow 2017 ]  
This is a multicenter, multinational, randomized, double -blind, placebo -controlled Phase 3 study 
designed to demonstrate the clinical efficacy and safety of lumasiran in patients with PH1.  The 
primary endpoint for the study is percent change  in 24 -hour urinary oxal ate excretion from 
baseline to Month 6. 
Urinary oxalate excretion is the most sensitive and clinically relevant marker that directly relates 
to the PH1 disease pathophysiology in this population, and is used clinically for diagnosis and 
management of patie nts with PH1 who have preserved renal function.  Elevated urinary oxalate 
is the direct cause of kidney stones and renal failure in patients with PH1.  Lowered urinary 
oxalate excretion is expected to provide clinical benefit in patients with preserved ren al function 
by directly targeting the cause of the disease: toxic urinary oxalate levels that lead  to oxalate 
Clinical Study Protocol ALN -GO1 -003 lumasiran  
Amendment  3, 06 May  2020 
Alnylam Pharmaceuticals  Confidential  29 crystallization in the kidneys and urinary tract.  Reduced urinary oxalate excretion therefore is 
expected to reduce kidney stone burden and poten tially stabilize renal function.  
The primary endpoint will evaluate the effect of lumasiran versus placebo on urinary oxalate at 
Month  6.  After 6 months, patients originally assigned to lumasiran will continue to receive 
lumasiran, and patients originally  assigned to placebo will receive lumasiran in a blinded 
extension period through Month 9 to preserve blinding.  Patients randomized to lumasiran will 
receive injections of placebo at Month 7 and Month 8 to maintain the blind. All patients will then 
be fol lowed in an open -label period of up to 51 months to evaluate the long -term safety and 
efficacy of lumasiran.  Use of a placebo comparator and limiting the duration of placebo 
exposure to the  6-month double -blind period are  appropriate based on the lack of approved 
therapies for patients with PH1 while allowing  an estimation of the treatment effect and an 
understanding of the safety profile of lumasiran.   All patients will continue their current standard 
of care regimen, which may include hyperhydration, cry stallization inhibitors, and/or pyridoxine 
therapy , for the first 12 months of the study, after which they can adjust per the 
recommendations of their treating physician.  Current disease management options are presented 
in Section  1.1. 
The study population will be comprised of children and adults wi th a documented diagnosis of 
PH1, elevated urinary oxalate, and GFR  ≥30 mL/min/1.73m2.  Lumasiran  is currently being 
investigated in a similar patient population (ie, patients with PH1 ≥6 years of age with relatively 
intact renal function ) in Study ALN -GO1 -001.  Enrolling pediatric patients  in this study  is 
acceptable given that PH1  presents as  a pedi atric disease with life -threatening consequences and 
hence there is a high unmet m edical need in this population . 
1.4. Dose Rationale  
Data from study  ALN -GO1 -001 Parts A and B in healthy subjects and PH1 patients and 
associated PK/PD  modeling  were  used to support  dose selection for this study.  The proposed 
dosing regimen for this study is 3 .0 mg/kg once monthly for 3 consecutive months  (monthly for 
3 doses : loading dose  phase ) followed by 3 .0 mg/kg once every 3 months (maintenance phase ) 
starting 1 month after the last loading dose.  This regimen is expected to be well -tolerated and to 
optimize the proportion of patients with a rapid and sustained reduction in urinary oxalate .  
In patients with PH1, population PK/PD modeling demonstrated  dose dependent oxalate 
reductions over the dose range (1.0 to 6.0  mg/kg  continuous  once monthly or once every 3 
months  SC administrations), with diminishing additional effect predicted with higher doses 
consistent with an asymptotic rather than linear relationship.  For a given dose,  the PK/PD model 
indicated that monthly administration leads to a more rapid decline in ur inary oxalate levels 
relati ve to  dosing  every 3 months .  A combination of monthly dosing in a loading phase and then 
dosing  every 3 months  in a maintenance phase achieves the goals of rapid and consistent 
lowering of urinary oxalate to normal or near norma l levels in PH1 patients .  Preclinical and 
clinical data indicate the renal pathway is a minor elimination route for lumasiran. Thus, renal 
impairment is not expected to influence systemic exposure, PD, and safety properties of 
lumasiran, and no dose adjus tments are needed based on renal function .  Thus, a lumasiran 
dosing regimen of 3.0 mg/kg once monthly  for 3 doses  followed by 3.0  mg/kg once every 3 
months  has been selected for this study  in PH1 patients ≥6 years old with eGFR 
>30 mL/min /1.73 m2.   
Clinical Study Protocol ALN -GO1 -003 lumasiran  
Amendment  3, 06 May  2020 
Alnylam Pharmaceuticals  Confidential  30 1.5. Benefit -Risk Assessment  
PH1 is a rare autosomal recessive disease characterized by excessive oxalate production by the 
liver leading to excessive urinary oxalate and varying types and degrees of renal disease, often 
progressing to end -stage renal disease. Systemic accumulation of calcium oxalate results in 
severe end -organ damage. Without treatment, the disease progresses, and patients die from end -
stage renal disease and/or complication of oxalosis.  
Lumasiran is designed to reduce hepatic production of ox alate. Based on the available data from 
nonclinical studies and the Phase  1 clinical study ALN -GO1 -001, lumasiran, administered 
subcutaneously, demonstrated a potent, dose -dependent inhibition of glycolate oxidase resulting 
in increased plasma and urinary glycolate and decreased urinary oxalate.  Unlike oxalate, 
glycolate is highly soluble and readily excreted in the urine. Thus, by reducing the production of 
oxalate, it is possible that lumasiran may ameliorate the signs and symptoms of PH1 and alter the 
clinical course in patients across the spectrum of disease, irrespective of age and disease stage.   
In the Phase 1 clinical study, lumasiran has been well tolerated with an acceptable safety profile 
based on the available safety data. Most adverse events ha ve been mild or moderate in severity. 
There have been no severe or serious adverse events related to study drug. Transient, mild 
injection site reactions (ISRs) have been observed but have not resulted in any treatment 
discontinuations or dose adjustments.  No clinical ly significant laboratory or hematologic 
changes have been observed.  
Given the biological target of lumasiran, the available nonclinical and clinical data, and mode of 
administration, important potential risks for lumasiran are injection site r eactions and liver 
function test abnormalities.  During the study, patients will be closely monitored, including 
evaluation of injection sites, laboratory monitoring for liver function test abnormalities, renal 
function, plasma and urine glycolate levels , and other standard hematology and blood 
chemistries . The study has specific inclusion and exclusion criteria to ensure that patients have 
adequate hepatic function and specific rules for dose withholding and stopping have been 
incorporated in the protocol for abnormalities in liver function tests . As the risk of embryofetal 
toxicity is currently unknown,  women of childbearing potential participating in the study must 
have a negative pregnancy test, cannot be breast feeding, and must be willing to use a high ly 
effective method of contraception as specified in the protocol.    
An external, independent Data Monitoring Committee (DMC) will monitor and ensure the safety 
of trial participants (see Section  3.7).  
Based on the emerging efficacy and safety data from the ongoing clinical study (ALN -GO1 -001) 
and nonclinical studies, the benefit -risk assessment is positive and supports the evaluation of 
lumasiran in a Phase 3 study in pediatric and adult patients with PH1.  
Detailed information about the known and expected benefits and risks of lumasiran may be 
found in the current edition of the Investigator’s Brochure.  
Clinical Study Protocol ALN -GO1 -003 lumasiran  
Amendment  3, 06 May  2020 
Alnylam Pharmaceuticals  Confidential  33 baseline collections will be used to determine eligibility for the study, defined as urinary oxalate 
excretion of ≥0.7 0 mmol/24h/1.73m2.  
Consenting (and assenting, where applicable) patients who meet all eligibility criteria will be 
randomized 2:1 to receive their first dose of subcutaneously administered lumasiran or placebo 
on Day 1.  Treatment groups will be stratified at randomization by mean urinary oxalate 
excretion from the first 2 valid baseline collections ( see Section  3.5). 
During the 6 -month, placebo -controlled, double -blind treatment period, patients will receive 
loading doses of 3.0  mg/kg lumasiran or placebo administered monthly for 3 doses (at Day 1, 
Month 1, and Month 2) followed by the first  maintenance dose of 3.0 mg/kg lumasiran or  
placebo  administered at Month 3  and then once every 3 months .   
After the Month 6 visit assessments are completed (ie, end of the 6 -month double -blind 
treatment period), patients from both treatment arms (lumasiran and placebo) will begin the 
3-month blinded treatment extension period, in which all patients will receive active drug.  To 
maintain the blind to treatment assignment, study drug will continue to be administered in a 
double -blind manner and at the same frequency as in the 6 -month double -blind period.  In the 
3-month treatment extension period, patients will receive study drug according to initial 
treatment assignment as follows:  
• Patients who had been randomized to placebo will receive 3.0 mg/kg lumasiran 
monthly at Months 6,  7, and 8  
• Patients who had been randomized to lumasiran will be given 3.0 mg/kg lumasiran at 
Month 6 and placebo at Months 7 and 8  
• All patients will be given a maintenance dose  of lumasiran  at Month 9  and then once 
every 3 months thereafter  
Assessments of  efficacy and safety will be co nducted during visits to the  clinical study center 
every 2 weeks for the first month of this part of the study and monthly thereafter through 
Month  9. 
Patients will receive their first open -label dose of lumasiran at Month 9 to begin their 
participation in the open -label extension (OLE) p art of the study, in which they will be treated 
with lumasiran administered  once every 3 months  for up to 48 months ; patients will receive their 
last dose of lumasiran at Month 57 .  Patients e ntering the OLE period will undergo effica cy and 
safety assessments every 3 months  through Month 24, and every 6 months until the end of study 
(EOS ) visit at Month  60. 
24-hour urine collections will be performed for evaluation of oxalate excretion.  At the Month 6 
and Month 12 visits, patients will provide at least three 24-hour urine collections  and ≥ 2 of these 
collections must be  valid  (see Section  6.3.1.1 ) prior to completion of the Month 6 and Month 12 
visit assessments.   Single 24 -hour urine collections will be obtained  for the study visits specified 
in the Schedules of Assessments .  Details on 24-hour urine collection procedures are included  in 
Section  6.3.1 .   
An external , indepe ndent DMC  will monitor safety over the course of the study.  Details for the 
committee will be provided in DMC charter.  
Clinical Study Protocol ALN -GO1 -003 lumasiran  
Amendment  3, 06 May  2020 
Alnylam Pharmaceuticals  Confidential  34 3.2. Duration of Treatment  
The duration of treatment with study  drug is up to  5 years , including a 6 -month double -blind 
treatment period followed by a 3-month blinded treatment extension period , and up to a 51 -
month open -label extension period . 
3.3. Duration of Study  
The estimated total time on study, inclusive of screening, for each  patient is up to 62 months, 
including up to 2 months of screening followed by up to 60 months of treatment (see  
Section  3.2). 
3.3.1.  Definition of End of Study for an Individual Patient  
A patient is considered to have reached the end of the study if:  
• the patient  has completed the e nd of study (EOS ; Month  60) visit , or  
• the patient  has completed the safety  follow -up visits until PD recovery of 24-hour 
urinary oxalate is >70% of baseline, and plasma glycolate is <30% above baseline or 
≤ the ULN,  or  
• the patient  has completed 12 months of monitoring follow ing the final lumasira n 
dose.   
3.4. Number of Planned Patients  
The planned enrollment for this study is 30 patients.  
3.5. Method of Assigning Patients to Treatment Groups  
Using the Interactive Response System (IRS), patients will be randomized 2:1 to the lumasiran 
or placebo arm.  Randomization will be stratified by mean baseline urinary oxalate level 
(>1.70 mmol/24h/1.73m2 versus ≤1.7 0 mmol/24h/1.73m2).  The mean urinary oxalate  level for 
stratification will be calculated using the values obtained from the first 2 valid baseline 24 -hour 
urine collections.  
Each patient will be uniquely identified in the study by a combination of the site number and 
patient identification number.  Upo n signing the informed consent form (ICF), the patient will be 
assigned a patient identification number by the IRS.  The Investigator or his/her designee will 
contact the IRS to randomize the patient after confirming that the patient fulfills all the inclu sion 
criteria and n one of the exclusion criteria.  
3.6. Blinding  
All site personnel (with the exception of some site pharmacists) and patients (including their 
families or caregivers) will be blinded to study drug treatment assignment until the last patient 
completes the assessments at the Month 9 visit.  Site pharmacists may be unblinded to study drug 
treatment only where required by documented pharmacy procedure.  All Sponsor personnel with 
direct oversight of the conduct and management of the study ( except fo r staff involved in 
randomization a nd study drug supply) will be blinded to study drug treatment  until the 6 -month 
Clinical Study Protocol ALN -GO1 -003 lumasiran  
Amendment  3, 06 May  2020 
Alnylam Pharmaceuticals  Confidential  35 treatment period data is unblinded for  the primary analysis .  Sponsor personnel who may have 
treatment assignment information will not have access to patient level data from the clinical trial 
databases.    
The independent DMC and an independent biostatistics group will have access to patient level 
treatment assignments.   
To maintain the blind to treatment assignment, d uring the 3-month blinded treatment extension 
period, study drug will continue to be administered in a double -blind manner and at the same 
frequency as in the 6 -month double -blind period .  However, the study is designed so that all 
patients will receive active drug during t he extension period according to initial treatment 
assignment as follows:  
• Patients randomized to placebo: 3 .0 mg/kg lumasiran administered as monthly  
loading doses (Month 6, 7, and 8)  
• Patients randomized to lumasiran: 3.0 mg/kg lumasiran administered as a single  
maintenance dose  at Month 6   
Therefore, all site personnel and patients will be aware that all patients will receive active drug 
administered at Month 6 even though all doses of study drug will be masked.   
The Sponsor and all  site personnel will be blinded to central l aboratory results of urinary and 
plasma oxalate and  glycolate from after the time of the first dose until unblinding .  Results  will 
not be reported to the I nvestigator  from the first dose to until the last patient completes the 
asses sments at the Month 9 visit .  In addition,  Investigators and staff involved with this trial and 
all medical staff involved in the patient’s medical care should refrain from obtaining local 
oxalate or  glycolate measurements until the sites and patients are unblinded , or until the patient 
ends the study, whichever is earlier .  If oxalate or gl ycolate is measured during the blinded 
period , all reasonable steps must be undertaken to avoid informing the patient and site personnel 
of the results  until the s ites and patients are unblinded . 
A list of all Alnylam personnel or personnel working on behalf of Alnylam who are unblinded to 
study data will be maintained in the trial master file ( TMF ).  Any unplanned unblinding 
occurring during the study period will be doc umented and reported in the clinical study report.   
Additional details are provided in a separate blinding plan.  
3.6.1.  Emergency Unblinding  
If the treating physician determines that the clinical management of the patient requires 
knowledge of the study drug assi gnment, the Investigator may break the blind, as necessary.  If 
time permits, clinical study center personnel should contact the Medical Monitor before 
unblinding to discuss the need to unblind the patient, but must do so within 1 working day after 
the unblinding event.  Unblind ing information should be limited to the fewest number of people 
on a need -to-know basis. A record of when the blind was broken, who was unblinded, who broke 
the blind, and why it was broken, will be maintained in the TMF .   
Refer to  the IRS instructions for details on unblindin g. 
Clinical Study Protocol ALN -GO1 -003 lumasiran  
Amendment  3, 06 May  2020 
Alnylam Pharmaceuticals  Confidential  36 3.7. Data Monitoring Committee  
An external independent DMC will oversee the safety and overall conduct of this study . The 
DMC will operate under the rules of a charter that will be reviewed and approved at the 
organizational meeting of the DMC. Details are provided in the DMC Charter.  
4. SELECTION AND WITHDR AWAL OF PATIENTS  
4.1. Inclusion Criteria  
Patients are eligible to be included in the study if all the following criteria apply:  
Age 
1. Age 6 years or older.   
Patient and  Disease Characteristics  
2. Documentation or confirmation of P H1 as determined by genetic analysis prior to 
randomization.  
3. Mean 24 -hour urinary oxalate excretion from the first 2 valid 24 -hour urine collections is 
≥0.70 mmol/24h/1.73m2  
4. If taking pyridoxine ( vitamin B6) for the treatment of PH1 , must have been on stable 
regimen for at least 90 days before randomization, and willing to remain on this stable 
regimen for 12 months from first study drug administration . 
Informed Consent  
5. Patient is able to understand and is willing and able to comply with the study 
requirements and to provide written informed consent.  In the case of patients under the 
age of legal consent, the legal guardian(s) must provide informed consent and the patient 
should pr ovide assent per local and national requirements.  
4.2. Exclusion Criteria  
Patients are excluded from the study if any of the following criteria apply:  
Disease -specific Conditions  
1. Medical history includes clinical evidence of extrarenal systemic oxalosis , as determined 
by the Investigator.  
Laboratory Assessments  
2. Has any of the following laboratory parameter assessments at screening:  
a. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2 × upper 
limit of normal (ULN)  
b. Total bilirubin >1.5 x ULN.   Patients with elevated total bilirubin that is secondary to 
documented Gilbert’s syndrome are eligible if the total bilirubin is <2 x ULN  
c. International normalized ratio (INR)  >1.5 (patients on oral anticoagulant [eg, 
warfarin] with an INR  <3.5 will b e allowed)  
Clinical Study Protocol ALN -GO1 -003 lumasiran  
Amendment  3, 06 May  2020 
Alnylam Pharmaceuticals  Confidential  37 3. Has known active human immunodeficiency virus (HIV) infection; or evidence of current 
or chronic hepatitis C virus (HCV) or hepatitis B virus (HBV) infection  
4. Estimated GFR of <30 mL/min/1.73m2 at screening (calculation will be based on the 
Modif ication of Diet in Renal Disease [MDRD] formula for patients ≥18  years of age and 
the Schwartz Bedside Formula for patients <18  years of age)  See Section  10.1  
Prior/Concomitant Therapy  
5. Received an investigational agent within the last 30 days or 5 half -lives, whichever is 
longer , prior to the first dose of study drug , or are in follow -up of another clinical study 
prior to randomization   
Medical Conditions  
6. History of renal or liver transplant  
7. Has other medical conditions or comorbidities, which in the opinion of the Investigator, 
would interfere with study compliance or data interpretation  
8. History of multiple drug allergies or history of allergic reaction to an oligonucleotide or 
GalNAc . 
9. History of intolerance to subcutaneous (SC) injection(s)  
Contraception, Pregnancy, and Breastfeeding  
10. Is not willing to comply with the contraceptive requirements during the study period, as 
described in Section 5.5.1 .  
11. Female patient is pregnant , planning a pregnancy,  or breast -feeding.  
Alcohol Use  
12. Unwilling or unable to limit alcohol consumption throughout the course of the study. 
Alcohol intake of >2 units/day is excluded during the study (unit: 1 glass of wine 
[approximately 125 mL] = 1 measure of spirits [approximately 1 fluid ounce] = ½ pint of 
beer [approximately 284 mL]  
13. History  of alcohol abuse, within  the last 12 months before screening, in the opinion of the 
investigator.  
4.3. Removal from Therapy or Assessment  
Patients or their legal guardians are free to discontinue study drug and/or stop participation in the 
study at any time and for any reason, without penalty to their continuing medical care.  The 
Investigator or the Sponsor may stop a patient’s participatio n in the study at any time if this is 
considered to be in the patient’s best interest.  Any discontinuation of treatment or the stopping 
of the patient’s participation in the study must be fully documented in the electronic case report 
form (eCRF), and sho uld be followed up by the Investigator.   
Discontinuation of study drug is described in Section 4.3.1 , while the stopping of a patient’s 
participatio n in the study is detailed in Section  4.3.2 . 
Clinical Study Protocol ALN -GO1 -003 lumasiran  
Amendment  3, 06 May  2020 
Alnylam Pharmaceuticals  Confidential  38 4.3.1.  Discontinuation of Study Drug  
The Investigator, or designee, may discontinue study drug in a patient, if  the patient:  
• Is in significant violation of the protocol  
• Experiences a serious or intolerable AE  
• Is non -adherent to treatment regimen  
• Becomes pregnant  
• Is lost to follow -up 
• Has another reason (non -adverse event)  
• Or, the study is terminated by the Sponsor  
The Investigator will confer with the Sponsor or Medical Monitor before discontinuing dosing in 
the patient.   
Patients who are pregnant will be discontinued from study drug dosing immediately (see 
Section  6.5.7.7  for reporting and follow -up of pregnancy).   A positive urine pregnancy test 
should be subsequently confirmed by a serum pregnancy test prior to discontinuing the study 
drug.  
If a patient disc ontinues dosing due to an adverse event ( AE), including serious adverse events 
(SAEs ), the event should be followed as described in Section  6.5.7 .  When a patient discontinues 
study drug dosing, the primary reason must be recorded in the appropriate section of the eCRF.  
Patients who discontinue study drug  and remain on study may receive treatment consistent with 
local standard practice for their dis ease per Investigator judgment, as applicable.  
Patients who discontinue from study drug prior to completion of the Month 6 assessments will be 
encouraged to remain on study and complete monthly assessments (including 24 -hour urine 
collections , but excluding PK assessments ) through Month 6.  They will then  be asked to 
complete safety follow -up visits  once every 3 months per the safety follow -up schedule  (see 
Table  2).  Patients who discontinue study drug after completion of the Month 6 assessments will 
be asked to return for their next scheduled visit to complete early termination ( ET) assessments 
and complete safety follow -up visits once every 3 mo nths thereafter  per the safety follow -up 
schedule  (see Table  2). 
While the study sites and patients remain blinded, the patient will be followed until 12 months 
after the last dose of lumasiran.  If the patient is still in follow -up at the time when sites and 
patients are unblinded, PD recovery should be evaluated to de termine if the patient meets the PD 
recovery criteria (ie, 24-hour urinary oxalate is >70% of baseline, and plasma glycolate is <30% 
above baseline or ≤ the ULN ) and is eligible to stop study follow -up. 
4.3.2.  Stopping a Patient's Study Participation  
A patient or  their legal guardian may stop participation in the study at any time.   Patients 
considering stopping their participation in the study during the blinded period of the study  should 
be informed that they can discontinue study drug  and complete their study a ssessments throu gh 
the Month 6 visit and complete safety follow -up visits as described in Section  4.3.1 , or 
alternatively may complete any minimal as sessments for which the patient or their legal guardian 
Clinical Study Protocol ALN -GO1 -003 lumasiran  
Amendment  3, 06 May  2020 
Alnylam Pharmaceuticals  Confidential  39 consents.  If a patient or their legal guardian chooses to discontinue study drug and stop 
participation in all follow -up prior to the completion of the Month 6 visit, every effort should be 
made to conduct the assessments scheduled to be performed at the Month 6 visit and the safety 
follow -up assessments (see Table  1).   
Patients or their legal guardians considering stopping participation in the study after the sites 
have been unblinded should be informed that they can discontinue study drug and complete 
safety follow -up visits as described in Section  4.3.1 , or alternatively may complete any minimal 
assessments for which the patient or legal guardian consents.   
If a patient or their legal guardian still chooses  to stop participation in the study, every effort 
should be made to conduct the ET assessments prior to stopping study participation (see 
Table  2). 
The patient may decide to withdraw consent, informing the study doctor at any time in writing or 
in any other form that may be locally required.  The Sponsor will continue to keep and use the 
patient’s study information (including any data resulting from the analysis of patient’s biological 
samples until the time of withdrawal) according to applicable law.  The process for the storage 
and, as applicable, further use of remaining samples will be followed per local requirements.  
The Investigator or Sponsor may s top the participation of a patient in the study at any time if this 
is considered to be in the patient’s best interest.  However, study integrity and interpretation is 
best maintained if all enrolled patients continue study assessments and follow -up even i f study 
drug is discontinued.  
The primary reason that a patient’s study participation is stopped must be recorded in the 
appropriate section of the eCRF and all efforts will be made to complete and report the 
observations as thoroughly as possible.   If a patient’s study participation is stopped due to an 
adverse event (AE), including SAEs, the event should be followed as described in  Section  6.5.7 . 
Patients stopping participation in  the study will be asked if they are willing to consent to either 
be contacted by telephone or to allow non -patient contact follow -up (eg, medical record review) 
up to  6 years after enrolling onto the study to document their  overall health status.  
4.3.3.  Replacement of Study Patients  
Patients who discontinue the study drug or stop participation in the study will not be replaced . 
4.3.4.  Lost to Follow -Up 
A patient will be considered lost to follow -up if the patient  repeatedly fails to return for 
scheduled visits and is unable to be contacted by the clinical study center.  The following actions 
must be taken if a patient misses  a required study visit:  
• The site must attempt to contact the patient and reschedule the mi ssed visit as soon as 
possible and counsel the patient on the importance of maintaining the assigned visit 
schedule and ascertain if the patient wishes to and/or should continue in the study.  
• Before a patient is deemed lost to follow up, the Investigator o r designee must make 
every effort to regain contact with the patient (where possible, 3 telephone calls and, if 
necessary,  a certified letter to the patient’s last known mailing address or local 
Clinical Study Protocol ALN -GO1 -003 lumasiran  
Amendment  3, 06 May  2020 
Alnylam Pharmaceuticals  Confidential  40 equivalent methods). These contact attempts should be docume nted in the patient’s 
medical record.  
• Should the patient continue to be unreachable, the patient will be considered to have 
stopped participation in the study.  
5. TREATMENTS AND OTHER  REQUIREMENTS  
5.1. Treatments Administered  
Study drug supplied for this study must not be used for any purpose other than the present study 
and must not be administered to any person not enrolled in the study.  Study drug that has been 
dispensed and returned unused must not be re -dispensed.  
5.2. Study Drug  
Detailed information describing  the preparation, administration, and storage of lumasiran and 
placebo is provided in the Pharmacy Manual.  
5.2.1.  Description  
Lumasiran will be supplied as a sterile solution in water for SC injection.  See the Pharmacy 
Manual for further details of solution conc entration and fill volume.  
The control drug for this study will be a placebo (sodium chloride 0.9% w/v for SC 
administration).  Placebo will be provided by the Sponsor; it will be packaged identically to 
lumasiran.  
5.2.2.  Dose and Administration  
Study drug is adm inistered based on total body weight.  Body weight collected within 4 months  
prior to the study drug dose or the predose weight collected on the study visit day or dosing day 
will be used for dose calculations.  
During the 6 -month double -blind treatment per iod (Day 1 through Month 6 assessments) , 
patients will be administered loading doses of 3.0  mg/kg lumasiran or an equivalent volume of 
placebo as an SC injection once monthly for 3 doses (administered at Day  1, Month 1, and 
Month  2 visits) followed by 1  maintenance dose of 3.0 mg/kg lumasiran or placebo administered 
at the Month  3 visit.  During the 3 -month blinded treatment extension period (from dosing at 
Month 6 [following completion of all assessments] through Assessments at Month 9) , patients 
randomize d to placebo will be administered loading doses of 3.0 mg/kg as an SC injection once 
monthly for 3 doses (administered at Month 6, Month 7, and Month 8 visits).  Patients 
randomized to lumasiran will continue to receive a maintenance dose at the Month 6 vi sit.  
Patients randomized to lumasiran will receive doses of placebo administered at the Month  7 and 
Month  8 visits to keep all procedures same between the lumasiran and placebo arm patients and 
maintain the blind.  
In order to maintain the blind to treatme nt assignment, study drug will continue to be 
administered in the blinded treatment extension period in a double -blind fashion.  However, due 
to study design features, both patients and study site personnel will be aware that all patients will 
Clinical Study Protocol ALN -GO1 -003 lumasiran  
Amendment  3, 06 May  2020 
Alnylam Pharmaceuticals  Confidential  41 receive acti ve drug at Month 6.  Patients will receive their first open -label maintenance dose of 
lumasiran at Month  9.   
Study drug injections will be administered under the supervision of the Investigator.  The 
injection site may be marked and mapped for later observation.  The site s of injection may be the 
abdomen , the upper arms , or thighs.  If a local reaction around the injection site occurs,  
photographs may be obtained.  Detailed instructions for study drug administration are found in 
the Pharmacy Manual.    
From Month  12 through the end of the study, study drug administration may be conducted at a 
location other than the study center ( eg, home) by a  healthcare professional with the oversight of 
the Investigator, where applicable country and local regulations  and infrastructure allow.  
However, continued study drug administration at the study center should be considered for  
patients who have ongoing study drug -related AEs, worsening injection site reactions with repeat 
dosing, or for anyone in the opinion of t he Investigator who would benefit from clinical 
observation following dosing.    
If the patient is unable to come to the study site, and a visit by a healthcare professional is not 
possible due to circumstances related to the COVID -19 pandemic, lumasiran ma y be 
administered by the patient or caregiver under the oversight of the Investigator, and following 
consultation with the Medical Monitor, as allowed by applicable country and local regulations.  
In such cases, the  patient or  caregiver must receive approp riate training on lumasiran 
administration prior to dosing.  This measure is intended to remain in effect only during periods 
of time when the COVID -19 pandemic impedes the ability of patients to travel to the study site 
and healthcare professionals to go to patients' homes for dosing.   
If a patient does not receive a dose of study drug within the specified dosing window, the 
Investigator should contact the Medical Monitor.  After such consultation, the dose may be 
administered or considered missed and not  administered.  
If a patient misses multiple doses  of study drug , the Investigator, in consultation with the 
Medical Monitor, will discuss whether the patient will be able to continue the study (see also  
Section  4.3). 
Additional details can be found in the Pharmacy Manual.   In addition, instructions and 
procedures related to administration of lumasiran by a patient or caregiver will be provided in the 
Patient/Caregiver Storage and Administration Instructions.  
5.2.3.  Dose Modifications  
Dose modifications are not permitted . 
If a study drug -related AE occurs in a patient that the Investigator judges as presenting a  
potential risk to the patient for further dosing, the study drug dose may be held at the discretion 
of the Investigator and the medical monitor should be contacted.    
5.2.3.1.  LFT Criteria for Withholding, Monitoring and Stopping Study Drug  Dosing  
1. LFT results from the previous visit should be reviewed prior to dosing.    
2. For any ALT or AST elevation >3 × ULN central laboratory results should be used to 
guide subsequent monitoring a s detailed in Table  6.  
Clinical Study Protocol ALN -GO1 -003 lumasiran  
Amendment  3, 06 May  2020 
Alnylam Pharmaceuticals  Confidential  42 3. For any ALT or AST elevation >3× ULN:  
a. If local laboratory results are obtained, c onfirm using central laboratory, as soon as 
possible, ideally within 2 to 3 days, but no later than 7 days.  
b. If an alternative cause is found, provide appropriate care.  
c. If an alternative cause is not found, p erform assessments per  Table  6 and Table  9. 
4. For any ALT or AST elevation >3× ULN without alternative cause  that is accompanied 
by clinical s ymptoms consistent with liver inju ry (eg , nausea, right upper quadrant 
abdominal pain, jaundice) or elevated bilirubin to ≥2× ULN or INR ≥1.5, permanently 
discontinue dosing.  
5. For confirmed ALT or AST elevations >3× ULN without alternative cause  and not 
accompanied by symptoms  or elevated bilirubin ≥2× ULN or INR ≥1.5, see Table  6 
(below):  
Clinical Study Protocol ALN -GO1 -003 lumasiran  
Amendment  3, 06 May  2020 
Alnylam Pharmaceuticals  Confidential  43 Table  6: Monitoring and Dosing Rules for Asymptomatic Patients with Confirmed 
Isolated Elevations of ALT and/or AST >3× ULN, with No Alternative Cause 
Identified  
Transaminase Level  Action  
>3× to 5× ULN  • May continue dosing  
• Evaluate the initial elevation in LFT per the following assessments:  
• Table  9 (all assessments to be performed once)  
• Hematology, serum chemistry , LFT per Table  8  
• Coagulation parameters ( prothrombin time, partial thromboplastin 
time, international normalized ratio ) 
• Monitor LFT at least every two weeks per Table  8. 
• If elevation persists for ≥2  months, must discuss with the medical monitor 
before continuing dosing  
>5× to 8× ULN  • Hold study drug  dosing until recovery to ≤1.5  × ULN  or baseline ; may 
resume dosing after discussion with the Medical Monitor  
• Evaluate the initial elevation in LFT per the following assessments  
• Table  9 (all assessments to be performed once)  
• Hematology, serum chemistry , LFT per Table  8  
• Coagulation parameters ( prothrombin time, partial thromboplastin 
time, international normalized ratio ) 
• Monitor LFT at least weekly  per Table  8 until ALT and/or AST is 
declining on 2 consecutive draws, then may decrease monitoring to 
biweekly  
• If ALT or AST rises to >5× ULN following resumption of dosing, 
permanently discontinue dosin g 
>8× ULN  Permanently discontinue dosing after confirmation of the transaminase value  at 
the central laboratory.  
Abbreviations: ALT=alanine transaminase; AST=aspartate transaminase; INR=international normalized ratio; 
LFT=liver function test(s); ULN=upper limit of normal.  
Notes:   In addition to these criteria, other assessments or evaluations may be performed per Investigator discretion, 
as appropriate.  
5.2.4.  Preparation, Handling, and Storage  
Staff at each clinical study center and the healthcare pro fessional will be responsible for 
preparation of lumasiran doses, according to procedures detailed in the Pharmacy Manual.  In 
cases where lumasiran is administered at home by a  patient or  caregiver, dosing may be prepared 
and administered by the patient/ caregiver according to procedures detailed in the 
Patient/Caregiver Storage and Administration Instructions.   No special procedures for the safe 
handling of study drug are  required.    
Study drug will be stored upright and refrigerated at approximately [5±3°C].  
A Sponsor representative or designee will be permitted, upon request, to audit the supplies, 
storage, dispensing procedures, and records.  
Clinical Study Protocol ALN -GO1 -003 lumasiran  
Amendment  3, 06 May  2020 
Alnylam Pharmaceuticals  Confidential  44 Instructions specific to unused study drug and additional storage will be provided in the 
Pharmacy Manual  and the Patient/Caregiver Storage and Administration Instructions . 
5.2.5.  Packaging and Labeling  
All packaging, labeling, and production of study drug will be in compliance with current Good 
Manufacturing Practice specifications, as well as applicable local regulations.  Study drug labels 
and external packaging will include all appropriate information  as per local labeling 
requirements.  Additional details will be available in the Pharmacy Manual.  
5.2.6.  Accountability  
The Investigator or designee will maintain accurate records of receipt and the condition of the 
study drug supplied for this study, including dates of receipt.  In addition, accurate records will 
be kept of when and how much study drug is dispensed and administered to each patient in the 
study.  Any reasons for departure from the protocol dispensing regimen must also be recorded.  
At the completi on of the study, there will be a final reconciliation of all study drugs.  Used, 
partially used, and unused study drug will be returned to the Sponsor (or designee) or destroyed 
at the clinical study center according to applicable regulations.  
Further inst ructions about drug accountability will be detailed in the Pharmacy Manual.  
5.3. Concomitant Medications  
Use of concomitant medications will be recorded on the patient’s eCRF as specified in the 
Schedules of Assessments (see Table  1 and Table  2).  This includes all prescription medications, 
herbal preparati ons, over the counter medications, vitamins, and minerals.  Any changes in 
medications during th e study will also be recorded in  the eCRF.  
If patients use NSAIDs intermittently or chronically, they must have been able to tolerate them 
with no previous side  effects (eg, gastric distress or bleeding).   
Standard vitamins and topical medications are permitted.  However, topical steroids must not be 
applied anywhere near the injection site(s) unless medically indicated.  If taking pyridoxine 
(vitamin B6 ) for the treatment of PH1 , patients must have been on stable regimen for at least 
90 days before randomization, and willing to remain on this stable regimen for 12 months from 
first study drug administration .  Patients should avoid high dose vitamin C preparati ons within 
4 days prior to oxalate assessments.   
For other permitted concomitant medications administered subcutaneously, do not administer in 
same injection site area as the study drug for 7 days after the last dose of study drug.  
Patients may be treate d for PH1 according to local standard of care.  Patients should continue 
their current standard of care regimen, including hyperhydration, crystallization inhibitors, 
and/or pyridoxine therapy for the first 12  months of the study .  Standard of care treatme nt may 
be adjusted beginning at Month  12 in accordance with clinical judgement.  
Any concomitant medication that is required for the patient’s welfare may be administered by the 
Investigator.  However, it is the responsibility of the Investigator to ensure that details regarding 
the medica tion are recorded on the eCRF.  Concomitant medication will be coded using an 
internationally recognized and accepted coding dictionary.  
Clinical Study Protocol ALN -GO1 -003 lumasiran  
Amendment  3, 06 May  2020 
Alnylam Pharmaceuticals  Confidential  45 5.4. Treatment Compliance  
Compliance with study drug administration will be verified by stu dy staff.  
5.5. Other Requirements  
5.5.1.  Contraception  
Women of child -bearing potential must be willing to use acceptable methods of contraception 
from 14  days before first dose, throughout study participation, and for 90  days after last dose 
administration or until s tudy completion.  Pediatric/adolescent female patients must initiate 
contraception at menarche or must discontinue study drug.  
Birth control methods which are considered acceptable include : 
• Placement of an intrauterine device.  
• Placement of an intrauterine hormone -releasing system.  
• Bilateral tubal occlusion.  
• Surgical sterilization of male partner (with the appropriate post -vasectomy 
documentation of the absence of sperm in the ejaculate; for female patients on the 
study, the vasectomized male partner should  be the sole partner for that patient).  
• Established use of oral, implantable, injectable, or transdermal hormonal methods of 
contraception. Women of child -bearing potential  who use hormonal contraceptives as 
a method of contraception must also use a barrie r method (condom or occlusive cap 
[diaphragm or cervical/vault cap] in conjunction with spermicide [eg, foam, gel, film, 
cream, or suppository]).   
• If hormonal methods of contraception are medically contraindicated due to their 
underlying disease, a double -barrier method (combination of male condom with cap, 
diaphragm, or sponge, in conjunction with spermicide) is also considered an 
acceptable method of contraception.  
• True sexual abstinence, when in line with the preferred and usual lifestyle of the 
patient .  Periodic abstinence (eg, calendar, ovulation, symptothermal, post -ovulation 
methods) and withdrawal are not acceptable methods of contraception.  Abstinent 
patients must agree to use one of the above -mentioned contraceptive methods, if they 
start hetero sexual relationships during the study and until study completion.  
Women of child -bearing potential include female patients who have experienced menarche (or 
begin menarche over the course of the study) and who are not postmenopausal or permanently 
steriliz ed (eg, bilateral tubal occlusion, hysterectomy, or bilateral salpingectomy).  A 
postmenopausal state is defined as the absence of menses for 12 months without an alternative 
medical cause , confirmed by follicle -stimulating hormone level  within the postmenopausal 
range.  
For male patients , no contraception is required.  However, use by males of contraception 
(condom) may be required in some countries, e.g., France, in order to comply with local 
requirements as described in the corresponding patient informed consent forms.   
Clinical Study Protocol ALN -GO1 -003 lumasiran  
Amendment  3, 06 May  2020 
Alnylam Pharmaceuticals  Confidential  46 Compliance with contraception requirements will be assessed on a regular basis by the 
Investigator throughout the course of the study.  
5.5.2.  Alcohol Restrictions  
Patients will limit alcohol consumption throughout the course of the study.   Alcohol is limited to 
no more than 2 units per day (unit:  1 glass of wine [approximately 125 mL] = 1 measure of 
spirits [approximately 1 fluid ounce] = ½ pint of beer [approximately 284 mL]) for the duration 
of the study.  
5.5.3.  Dietary Restrictions  
Patients s hould refrain from consumption of foods with high oxalate content, including, but not 
limited to, chocolate, rhubarb, spinach, and beet root, for 1 week prior to assessments of urinary 
and plasma oxalate.  
6. STUDY ASSESSMENTS  
The schedule s of study assessmen ts is provided in Table  1, Table  2, Table  3, and Table  4.   
Where applicable count ry and local regulations and infrastructure allow for home healthcare, 
healthcare may take place at a location other than the clinical trial site to perform study 
assessments, which may include pregnancy test ing (urine or serum), clinical lab oratory  
assess ments, urine collections, DNA testing, symptom -directed physical examination / body 
system assessment , vital signs, body weight, height, PK and PD blood collection, blood 
collection for vitamin B6 levels, ADA and exploratory analyses (blood and urine) asse ssments , 
at all timepoints as specified in the Schedule of Assessments . 
6.1. Screening Assessments  
An informed consent form (ICF) or assent form in the case of patients under the age of legal 
consent that has been approved by the appropriate Institutional Review Board (IRB)/Independent 
Ethics Committee (IEC) must be signed by the patient (or legal guardian  if under the age of legal 
consent ) before the Screening procedures are initiated.  All patients (or their legal guardians  if 
under the age of legal conse nt) will be given a copy of the signed and dated ICF and/or assent 
form .  In the case when a patient reaches the legal age of consent  during the study , the 
investigator must obtain the patient's informed consent prior to performing any further study 
interv entions and/or procedures involving that patient  (see Section  8.1.1 ). 
Patients will be screened to ensure that they meet all the inclusion criteria a nd none of the 
exclusion criteria (see Section  4.1 and Section  4.2).   
Patient demographic data and medical history/disease history will be obtained.  Any changes to 
medical history occurring between the screening assessment and Day 1 will be updated prior t o 
study drug administration.  
A blood sample for PH1/ AGXT  mutation analysis will be collected for patients who do not have 
documented PH1 genetic analysis to confirm eligibility.  
Clinical Study Protocol ALN -GO1 -003 lumasiran  
Amendment  3, 06 May  2020 
Alnylam Pharmaceuticals  Confidential  47 During the screening period, at least 3 separate 24 -hour urine collections wi ll be completed to 
assess urinary oxalate excretion.  Patients are strongly encouraged to complete these collections 
during supervised visits unless they are already familiar with the collection procedures.  At least 
2 of these collections need to be confi rmed to be valid collections (see Section  6.3.1.1 ) prior to 
receiving study drug on Day 1.  The mean urinary oxalate excretion from the first 2 valid  
baseline collections will be used to determine eligibility for the study (see Section  4.1) and 
randomization stratification.  
6.1.1.  Retesting   
If in the Investigator’s judgement,  the screening laboratory abnormalities are likely to be 
transient, then laboratory tests , excluding urinary oxalate,  may be repeated .  The investigator’s 
rationale is to be documented.  Laboratory values can be retested once durin g Screening as long 
as the patient can be evaluated for eligibility and randomized within the allowed Screening 
period.  
6.1.2.  Rescreening  
A patient who does not meet all study eligibility criteria may be allowed to return for rescreening 
if appropriate in the op inion of the investigator and after consultation with the Medical Monitor.  
A patient will be re -consented and assent obtained (if applicable) if rescreening occurs outside of 
the 60 -day screening window.  In this case, all screening procedures must be rep eated .  
6.2. Efficacy Assessments  
The efficacy of lumasiran will be assessed by evaluating the percent change in 24 -hour urinary 
oxalate excretion determined from 24 -hour urine sample collections described in Section  6.3.1 . 
6.3. Pharmacodynamic and Renal Assessments  
Urine and blood samples will be collected for assessment of PD parameters (plasma and urinary 
oxalate and glycolate concentrations) and renal parame ters at the time points specified in the 
Schedules of Assessments ( Table  1 and Table  2).  All blood and urine samples will be collected 
prior to dosing, if applic able.  
Where local regulations allow and  infrastructure is in place, home nursing may be used to coll ect 
urine samples or for repeat blood sample collection, if necessary.  
6.3.1.  24-hour Urine Collections to determine Urinary Oxalate Excretion  
Urinary oxalate excretion will be determined from 24 -hour urine sample collections to be 
completed at the time points specified in the Schedules of Assessment ( Table  1 and Table  2) to 
assess urinary oxalate excretion.  Urinary oxalate concentrations will be analyzed centrally using 
a validated assay.  The duration of collection and volume of urine in the collection will be 
recorded in the eCRF.   An aliquot of the 24 -hour urine collection will also be used to determine 
urinary creatinine content to determine if the 24 -hour urine collections need to be repeated (see 
Section  6.3.1.1 ).  
Single void collections for random urine sample for PD analysis should be collected as a first 
morning void when possible.  
Clinical Study Protocol ALN -GO1 -003 lumasiran  
Amendment  3, 06 May  2020 
Alnylam Pharmaceuticals  Confidential  48 Table  7 shows the 24 -hour urine collection procedure by study visit.  
Table  7: 24-hour Urine Collection Procedure  by St udy Visit  
Study Visit and Urine 
Collection Window  Number of 
Collections 
to Schedule  Validity 
Requirement  
Prior to Dosing 
(see Sec 6.3.1.1 ) Option  for 
Catheterized 
Collection?  Notes  
Screening  
(within 60 -day period)  3 2 valid 
collections prior 
to dosing  No Supervised collections are 
encouraged unless patient 
already familiar with collection 
procedure. If any collections are 
invalid, the remaining 
collections for screening must be 
supervised.  
Month 6 and Month 12  
(within 14 days prior to 
dosing)  3 2 valid 
collections prior 
to dosing  Yes If a patient has had ≥2 prior 
invalid collections, all 3 
collections must be supervised.  
At least 2 valid collections must 
be obtained prior to dosing. If 
any collections for the timepoint 
are invalid, the remaining 
collecti ons for the timepoint 
must be supervised.  
Interim Monthly Visits 
with D osing  
(Months  1-3 and Months  7-9 
[within 7  days prior to 
dosing])  1 No Yes If invalid collection is obtained  
for the timepoint , single repeat 
collection must be supervised.  
Repeat collection, if necessary, 
is to be completed within 
±7 days of dosing.  
Interim Monthly Visits 
Without D osing  
(Month  4 and Month  5 
[within 7  days prior to visit])  1 No Yes If invalid collection is obtained  
for the timepoint , single repeat 
collection must be supervised. 
Repeat collection, if necessary, 
is to be completed within 
±7 days of the visit.  
Visits after Month 12  
(within 14 days prior to visit)  1 No Yes If collection is invalid  for the 
timepoint , single repeat 
collection must be obtained 
within ±14  days of the visit. 
Dose should not be held if 
validity results unknown prior to 
dosing.  
Safety Follow -up Visits  
(within ±7 days of visit)  1 No Yes Repeat collections are optional.  
Abbreviations: Sec=section  
Note s: 
• Any or all of the 24 -hour urine collections may be conducted supervised.   If 24-hour urine is not a 
supervised collection, patients may either bring 24 -hour urine collections to the clinic or  have it couriered 
to the designated laboratory.  
• Optional catheterized collections are permitted  at any visit after initial study drug administration at the 
discretion of the Investigator with agreement of patient and /or legal guardian, if applicable .  
Clinical Study Protocol ALN -GO1 -003 lumasiran  
Amendment  3, 06 May  2020 
Alnylam Pharmaceuticals  Confidential  49 6.3.1.1.  Validity Criteria for 24 -hour Urine Collections  
A urine collection will be considered valid if each  of the following criteria are met:  
• The collection is between 22 -26 hours in duration between the initial discarded void 
and the last void or attempt to void.  
• No voids are missed between the start and end time of the collection  as indicated by 
the patient's urine collection diary . 
• The 24 -hour creatinine content is at least 1 0 mg/kg as assessed by the  central 
laboratory.  
6.3.1.2.  Urinary Oxalate: Creatinine Ratio 
Urine oxalate:creatinine ratios will be calculated from the oxalate and creat inine levels measured 
in the 24 -hour urine collections to assess the PD effect of lumasiran on urinary oxalate:creatinine 
ratio.  Urinary oxalate :creatinine ratios from random spot urine collections will also be 
measured.  
6.3.2.  Estimated Glomerular Filtration Ra te 
Blood samples for the assessment of eGFR will be obtained at the time points specified in the 
Schedules of Assessment ( Table  1 and Table  2).  eGFR (mL/min/1.73m2) will be calculated to 
assess renal function during the study.  The calculation will be based on the Modification of Diet 
in Renal Disease (MDRD) formula for patients ≥18 years of age and the Schwartz Bedside 
Formula for patients <18  years of age at screening  (Appendix  10.1).[Levey 2009 ; Schwartz 
2009 ]  
6.3.3.  Renal Stone Events  
A renal stone event is defined as an event which includes at least one of the following:  
• Visit to healthcare provider (eg, outpatient clinic, urgent care, emergency department, 
procedure) because of a renal stone  
• Medication for renal colic  
• Stone passage  
• Macroscopic hematuria due to a renal stone  
All relevant clinical information pertaining to the event should be obtained, including laboratory 
values, medical records, discharge summaries, and medical test results.    
Since renal stone events are recorded as an efficacy assessment for lumasiran, these will not be 
treated as AEs  or SAE s.  However, if a patient experiences other AEs  or SAEs  during a renal 
stone event, they should be reported  (see Section  6.5.7.1 ). 
6.3.4.  Sample Analysis  
All PD assessments will be analyzed centrally.  Details on the blinding of study results are 
provided in Section  3.6.  
Cli nic al St u d y Pr ot oc ol A L N -G O 1 -0 0 3  l u m asir a n 
A me n d me nt  3, 0 6  M a y  2 0 2 0  
Al n yl a m P h ar m ace utic als  C o nfi de nti al  5 0  Details re gar di n g t h e pr ocessi n g a n d ali q u oti n g of sa m ples f or st ora ge a n d a nal ys es will be 
pr o vi de d i n t he La b orat or y M a n ual.  
6. 4.  P h ar m ac o ki netic Assess me nts  
Bl o o d sa m ples will be c ollecte d f or t he assess me nt of l u masira n P K para m eters  i ncl u di n g 
meta b olites (as necessar y)  at t he ti me p oi nts i n dicate d i n t he Sc he d ules of Assess me nts ( Ta ble  1  
Ta ble  2 ).  A d etaile d sc h e d ule of ti me p oi nts f or t he c ollecti o n of bl o o d sa m ples f or P K a nal ysis 
is i n Ta ble  3  a n d Ta ble  4  (f or patie nts at E ast Asia n St u d y C e nters; see Secti o n  6. 4. 1 ). 
T he c o nce ntrati o n of l u m asira n i n bl o o d sa m ples will be deter mi ne d usi n g a vali date d ass a y.  
Details re gar di n g s a m ple v ol u mes t o be  c ollecte d, a n d t he pr ocessi n g, s hi p pi n g, a n d a nal ysis of 
t he sa m ples will be pr o vi de d i n t he La b orat or y Ma n ual. 
6. 4. 1.  P h ar m a c o ki netic Assess me nts i n P atie nts at  E ast Asi a n St u d y  Ce nters  
I n p atie nts w h o are i n e nr olle d at East Asia n sites, w hic h i ncl u de sites i n C hi na, K orea, J a pa n, 
Tai wa n, a n d H o n g K o n g, bl o o d a n d uri ne sa m ples f or P K a nal ysis will be c ollecte d at t he ti me 
p oi nts i n dicate d i n Ta ble  4  a n d Ta ble  5 . 
Plas ma P K para meters s u c h as C ma x, tma x, t½ β, A U C, C L/ F, a n d V/ F will be calc ulate d f or t he 
l u masira n plas ma c o nce ntrati o n pr ofiles.  I n a d diti o n, uri ne P K para m eters will be calc ulate d 
usi n g p o ole d uri ne s a m ples c ollecte d o v er 2 4  h o urs fr o m patie nts at East Asia n st u d y ce nters 
acc or di n g t o t he s c he d ule pr o vi de d i n Ta ble  5 . 
6. 5.  S afet y Assess me nts  
T he assess me nt of s afet y d uri n g t he st u d y will c o nsist of t he s ur veilla nce a n d rec or di n g of A Es  
i ncl u di n g seri o us a d v erse e ve nts ( S A Es), rec or di n g of c o nc o mita nt me dicati o n a n d 
meas ure me nts of vital si g ns,  w ei g ht a n d hei g ht, p h ysical e x a mi nati o n, a n d electr ocar di o gra m 
(E C G ) fi n di n gs a n d la b orat or y t ests. 
Safet y will be m o nit ore d o ver t he c o urse of t he st u d y b y a  D M C  as descri be d i n  Secti o n  3. 7 . 
6. 5. 1.  Vit al Si g ns  
Vital si g ns will be meas ure d as s pe cifie d i n t he Sc he d ules of Assess me nts ( Ta ble  1  a n d T a ble  2 ) 
a n d i ncl u de bl o o d press ure, heart rate, b o d y t e m perat ure, a n d res pir at or y rat e.  Vital si g ns will be 
me as ure d pre d ose, w h e n a p plic a ble.  O n Da y  1 a n d M o nt h 6 o nl y, vital si g ns will als o be 
meas ure d 3 0  ±  1 0  mi n utes p ost d ose.  W he n vital si g ns a n d bl o o d sa m ple c ollecti o n occ ur at t he 
sa me ti me, vital si g ns s h o ul d be perf or m e d bef ore bl o o d sa m ples are dra w n, w here p ossi ble. 
Vital si g ns s h o ul d be me as ure d i n t he seate d or s u pi ne p ositi o n, after t he patie nt has reste d 
c o mf orta bl y f or 1 0 mi n ut es.  Bl o o d pr ess ure s h o ul d be ta ke n usi n g t he sa m e ar m.  B o d y 
te m perat ur e i n de grees Celsi us will be o btai ne d via oral, t y m p a nic, or a xillar y met h o ds.  Heart 
rate will be c o u nte d f or a f ull mi n ute a n d rec or de d i n beats per mi n ute, a n d res pirati o n rat e will 
be c o u nte d f or a f ull mi n ute a n d rec or de d i n br eat hs per mi n ute.  
A d diti o nal vital si g n assess me nts, as me di call y i n dicate d, ma y be a d de d at t he discr eti o n of t he 
I n v esti gat or, or as p er D M C a d vice. 
Vital si g ns res ults will be rec or de d i n t he e C R F.  
Clinical Study Protocol ALN -GO1 -003 lumasiran  
Amendment  3, 06 May  2020 
Alnylam Pharmaceuticals  Confidential  51 6.5.2.  Weight and Height  
Height will be measured in centimeters.   For patients <18  years of age  at the study visit , height 
will be measured in triplicate.   Body wei ght will be measured in kilograms.  Height and body 
weight measurements will be collected as specified in the Schedules of Assessments ( Table  1 
and Table  2) and will be recorded in the eCRF .  Body weight  collected within 4 months  prior to 
the study drug dose or the predose weight collected on the study  visit day  or dosing day  will be 
used for dose calculations.    
6.5.3.  Physical Examination  
Full and symptom -directed physical examinations  will be conducted according to the Schedules 
of Assessments ( Table  1 and Table  2); if a physical examination is scheduled for a dosing visit, it 
should be conducted prior t o dosing.  Full p hysical examinations will include the examination of 
the following:  general appearance; head, eyes, ears, nose and throat; respiratory, cardiovascular, 
gastrointestinal, musculoskeletal, and dermatological systems; thyroid; lymph nodes; a nd 
neurological status.   If a visit is conducted offsite (eg, home), a  body system assessment may be 
performed in lieu of a physical examination.  
Symptom -directed physical examinations will be guided by evaluation of changes in symptoms, 
or the onset of new symptoms, since the last visit.  
Physical examination notes regarding any observed abnormalities will be recorded in the eCRF.  
6.5.4.  Electrocardiogram  
12-lead ECGs will be obtained, as specified in the Schedule s of Assessments (Table  1 and 
Table  2).  Specific timepoints and details regarding  the method of ECG acquisition 
(local/singlicate or central/triplicate) are provided in Table  3 and Table  4.  Patients should be 
supine for at least 10  minutes before each ECG is obta ined.   Triplicate  12-lead ECGs will have 
readings approximately 5  minutes apart  and will be centrally read . 
When ECG and blood sample collection occur at the same time, ECGs should be performed 
before blood samples are drawn , when  possible.  
The Investiga tor or qualified designee will review all ECGs to assess whether the results have 
changed since the Baseline visit and to determine the clinical significance of the results.  These  
assessments will be recorded in  the eCRF.  Additional ECGs may be collected  at the discretion 
of the Investigator, or as per DMC advice.  Recordings will be archived according to the Study 
Manual.  
During periods of time when the COVID -19 pandemic impedes the ability of patients to travel to 
the study site,  ECG assessments may be completed up to 7 months after the intended timepoint 
for visits at Month  12 and later. 
6.5.5.  Renal Ultrasound  
Renal ultrasound s will be obtained  as specified in the Schedules of Assessments ( Table  1 and 
Table  2).  Renal ultrasound will be performed according to instructions provided in the Study 
Manual  in a standardized manner .  Renal ultrasound s will be reviewed centrally and those 
obtained at Screening and M onth 6 will be read in a blinded manner.   
Clinical Study Protocol ALN -GO1 -003 lumasiran  
Amendment  3, 06 May  2020 
Alnylam Pharmaceuticals  Confidential  52 During periods of time when the COVID -19 pandemic impedes the ability of patients to travel to 
the study site,  renal ultrasounds may be completed up to 7 months after the intended timepoint 
for visits at Month  12 and later.  
6.5.6.  Clinical Laboratory Assessments  
The following clinical laboratory tests will be evaluated by a central laboratory.  S pecific 
instructions for transaminase elevations are provided in Section  5.2.3.1 .  For any other 
unexplained clinically relevant abnormal laboratory  test occurring after study drug 
administration, the test should be repeated and followed up at the discretion of the Investigator, 
or as per DMC advice, until it has returned to the normal range or stabilized, and/or a diagnosis 
is made to adequately expl ain the abnormality.  Additional safety laboratories and assessments as 
indicated by the clinical situation may be requested.  Clinical laboratory assessments are listed in 
Table  8 and will be assessed as specified in the Schedule of Assessments  (Table  1 and Table  2). 
While local laboratory results may be used for urgent clinical and dosing decisions, on the day of 
the clinic visit assessments, all laboratory assessm ents specified in Table  8 which are performed 
at the clinic should also be sent in parallel to the central laboratory.   Central laboratory results  
(once available) should be used for subsequent clinical and dosing decisions in the case of 
discrepant local and central laboratory results on samples drawn on the same day.   
For any safety event or laboratory abnormality, additional laboratory assessments, im aging, and 
consultation may be performed for clinical evaluation and/or in consultation with the Medical 
Monitor; results may be collected and should be included in the clinical database.  
Clinical laboratory assessments may be collected  at the clinical site or at a location other than the 
clinical study center  by a trained healthcare professional.  
Clinical Study Protocol ALN -GO1 -003 lumasiran  
Amendment  3, 06 May  2020 
Alnylam Pharmaceuticals  Confidential  53 Table  8: Clinical Laboratory Assessments  
Hematology  
Complete blood count with differential   
Serum Chemistry  
Sodium  Potassium  
BUN  Phosphate  
Creatinine and eGFR (usi ng the MDRD formula for 
adults [ ≥18 years of age at screening ] or the Bedside 
Schwartz formula for c hildren <18  years at 
screening ) Albumin  
Uric acid  Calcium  
Total protein  Carbon dioxide  
Glucose  Chloride  
Pyridoxine (vitamin B6)a  
Liver Function Tests   
AST  ALP  
ALT  Bilirubin (total and direct)  
Urinalysis  
Visual inspection for appearance and color  Bilirubin  
pH (dipstick)  Nitrite  
Specific gravity  RBCs  
Ketones  Urobilinogen  
Albumin  Leukocytes  
Glucose  Microscopy (if clinically indicated)  
Protein   
Abbreviations:  ALP=alkaline phosphatase; ALT=alanine transaminase; AST=aspartate transaminase; BUN=blood 
urea nitrogen; eGFR=estimated glomerular filtration rate; MDRD=modification of diet in renal disease; 
PH1= primary hyperoxaluria t ype 1; RBC=red blood cell  
a Pyridoxine  (vitamin B6)  is required through Month 18 and only for patients receiving vitamin B6 for the treatment 
of PH1.  On days when a blood sample for pyridoxine will be collected, patients should be instructed not to take 
vitami n B6 within 6 hours prior to blood sample collection.  
6.5.6.1.  Immunogenicity  
Blood samples will be collected to evaluate antidrug antibodies.  Blood samples for antidrug 
antibody testing must be collected before study drug administration as specified in the Sched ules 
of Assessments ( Table  1 and Table  2).  A bl ood sample to evaluate antidrug antibodies will be 
collected at the Early Termination  (ET)  visit, if applicable.  
Details regarding the processing, shipping, and analysis of the samples will be provided in the 
Laboratory Manual.  
Clinical Study Protocol ALN -GO1 -003 lumasiran  
Amendment  3, 06 May  2020 
Alnylam Pharmaceuticals  Confidential  54 6.5.6.2.  Pregnancy Testing  
A pregnanc y test will be performed for women of child -bearing potential, and for 
pediatric/adolescent females upon initiation of menarche.  A serum pregnancy test will be 
performed at Screening  or upon initiation of menarche, if applicable,  and urine pregnancy tests 
will be performed thereafter per the Schedule of Assessments and any time pregnancy is 
suspected.  More frequent pregnancy testing may be performed where required per local 
requirements .  The results of the pregnancy test must be  known before study drug administration.  
Patients who are pregnant at Screening are not eligible for study participation.  Any woman with 
a positive urine pregnancy test, subsequently confirmed by a positive serum pregnancy test, 
during the study will be discontinued from study drug, but will continue to be followed for 
safety.  Patients determined to be pregnant while on study will be followed at least until the 
pregnancy outcome is known (see Section 6.5.7.7  for follow -up instructions).   
Pregnancy testing may be performed offsite by a patient/caregiver if the patient/caregiver will be 
administering study drug.    
6.5.6.3.  Additional Liver Function Assessments   
Additional laboratory assessments will be performed in patients who experience any LFT 
abnormalities as outlined in Section  5.2.3.1 .  Following the occurrence of elevated liver 
transaminases or other LFT abnormalities per central laboratory, all assessments in Table  9 will 
be performed one time , as well as hematology, serum chemistry, LFT s from Table  8, and 
coagulatio n parameters , and other assessments or evaluations per Investigator discretion, as 
appropriate .   
Monitoring, including criteria for withholding  the study drug, are described in Section  5.2.3.1 . 
Clinical Study Protocol ALN -GO1 -003 lumasiran  
Amendment  3, 06 May  2020 
Alnylam Pharmaceuticals  Confidential  55 Table  9: Hepatic Assessm ents in Patients Who Experience Elevated Transaminases  
Extended Hepatic Panel  
Herpes Simplex Virus 1 and 2 antibody IgM, IgG  Herpes Zoster Virus IgM, IgG  
HIV 1 and 2a HHV -6  
Cytomegalovirus antibodies, IgM, IgG  HBs Ag, HBc antibody IgM and IgG  
Anti-nuclear antibodies  Epstein -Barr Virus antibodies, IgM and IgG  
Anti-smooth muscle antibodies  Anti-mitochondrial antibodies  
HCV antibody  HAV antibody IgM  
HCV RNA PCR – qualitative and quantitative  HEV antibody IgM  
Imaging  
Abdominal ultrasound with Doppler flow (or CT or MRI) including right upper quadrant  
Focused Medical and Travel History  
Use of any potentially hepatotoxic concomitant 
medications, including over the counter medications 
and herbal remedies  Alcohol consumption  
Other potentially hepatotoxic agents including any 
work -related exposures  Recent travels to areas where hepatitis A or E 
is endemic  
Abbreviations:  CT=computed tomography; HAV=hepatitis A virus; HBc=hepatitis B core; HBsAg=hepatitis B 
virus surface antigen; HCV=hepatitis C virus; HEV=hepatitis E virus; HHV -6=human herpesvirus 6; HIV=human 
immunodeficiency virus; IgG=immunoglobulin G antibody; IgM=immu noglobulin M antibody; MRI=magnetic 
resonance imagery; PCR=polymerase chain reaction; RNA=ribonucleic acid.  
Note:  
• All assessments will be measured in central laboratory. The full panel of assessments should only be 
performed once; individual assessments ma y be repeated, as needed.  
 a HIV testing will not be performed where prohibited by local regulations.  
6.5.6.4.  Maximum Blood Volume  
The maximum blood volume, which will be collected from pediatric patients over the course of 
the study, will be based on age and weight and will not exceed those specified in Table  10 from 
the Feinstein Institute for Medical Research Human Subject Protection Program Guidance 
Document (Section  10.2 in the Appendix). [Feinstein Institute 2013 ]  Collections per the SOA do 
not exceed the maximum 24 -hour or 30 -day volume limits for a 15 kg child who is not at an East 
Asian site.  At East Asian sites, if a patient weighs less than 30 kg, th en PK blood  samples 
should be limited to 1  ml at each time point and the blood samples for exploratory analyses 
should not be drawn.  
Clinical Study Protocol ALN -GO1 -003 lumasiran  
Amendment  3, 06 May  2020 
Alnylam Pharmaceuticals  Confidential  56 6.5.7.  Adverse Events  
6.5.7.1.  Definitions  
Adverse Event  
According to the International Council on Harmonisation (ICH) E2A guideline Defin itions and 
Standards for Expedited Reporting, and 21 CFR 312.32, IND Safety Reporting, an adverse event 
(AE) is any untoward medical occurrence in a patient or clinical investigational subject 
administered a medicinal product and which does not necessarily  have a causal relationship with 
this treatment.  
Renal stone events (as defined in Section  6.3.3 ) are recorded for efficacy assessment of  
lumasiran .  These events will not be treated as AEs or SAEs.   Other AEs or SAEs occurring 
during a renal stone event are reported . 
Serious Adverse Eve nt 
A serious adverse event (SAE) is any untoward medical occurrence that at any dose:  
• Results in death  
• Is life -threatening (an event which places the patient at immediate risk of death from 
the event as it occurred.  It does not include an event that had i t occurred in a more 
severe form might have caused death)  
• Requires in -patient hospitalization or prolongation of existing hospitalization  
• Results in persistent or significant disability or incapacity  
• Is a congenital anomaly or birth defect  
• Is an important medical event that may not be immediately life -threatening or result 
in death or hospitalization but may jeopardize the patient and may require 
intervention to prevent one of the other outcomes listed in the definition above (eg, 
events include allergic br onchospasm requiring intensive treatment in an emergency 
room or at home, blood dyscrasias, convulsions, or the development of drug 
dependency or abuse).  
Adverse Events of Clinical Interest  
The following are considered to be AEs of clinical interest:  
• Alan ine aminotransferase (ALT) or aspartate aminotransferase (AST) >3× upper limit 
of normal (ULN)  
• Severe or serious injection site reactions (ISRs); ISRs that are associated with a recall 
phenomenon (reaction at the site of a prior injection with subsequent injections), or 
those that lead to temporary dose interruption or permanent discontinuation of study 
drug.  
An ISR is defined as a local reaction at or near the site of injection.  “At or near” the 
injection site includes reactions at the injection site, ad jacent to the injection site, or a 
reaction which may shift slightly away from the injection site due to gravity (eg, as 
may occur with swelling or hematoma).  Reactions with onset and resolution within 
Clinical Study Protocol ALN -GO1 -003 lumasiran  
Amendment  3, 06 May  2020 
Alnylam Pharmaceuticals  Confidential  57 4 hours of the injection (eg, transient pain/burning at injection site) do not meet the 
study definition of ISRs, unless immediate treatment is required.  A systemic reaction 
which includes the injection site, eg, generalized urticaria, other distinct entities or 
conditions like lymphadenopathy that may be n ear the injection site is not considered 
an ISR.  
For information on recording and reporting of AEs of clinical interest, see Section  6.5.7.2  and 
Section  6.5.7.3  , respectively.  
Adverse Event Severity  
Adverse events are to be  graded according to the categories detailed below:  
Mild:  Mild; asymptomatic or mild symptoms; clinical or diagnostic 
observations only; intervention not indicated.  
Moderate:  Moderate; minimal, local or noninvasive intervention indicated; limiting 
age appropriate instrumental activities of daily living (eg, preparing 
meals, shopping for groceries or clothes, using the telephone, managing 
money).  
Severe:  Severe or medically significant but not immediately life -threatening; 
hospitalization or prolongatio n of hospitalization indicated; disabling; 
limiting self -care activities of daily living (ie, bathing, dressing and 
undressing, feeding self, using the toilet, taking medications, and not 
bedridden); OR life -threatening consequences; urgent intervention 
indicated; OR death related to an adverse event.  
Changes in severity should be documented in the medical record to allow assessment of the 
duration of the event at each level of severity.  Adverse events characterized as intermittent 
require documentation o f the start and stop of each incidence.  When changes in the severity of 
an AE occur more frequently than once a day, the maximum severity for the experience that day 
should be noted.  If the severity category changes over a number of days, then those chan ges 
should be recorded separately (with distinct onset dates).  
AE severity and seriousness are assessed independently.  ‘Severity’ characterizes the intensity of 
an AE.  ‘Serious’ is a regulatory definition and serves as a guide to the Sponsor for defining  
regulatory reporting obligations (see definition for SAE).  
Relationship of the Adverse Event to Study Drug  
The relationship of each AE to study drug should be evaluated by the Investigator by a “yes” or 
“no” response to the question: “Is there a reasonab le possibility that the event may have been 
caused by the study drug?”  A “yes” response indicates that the event is considered as related to 
the study drug.  
6.5.7.2.  Eliciting and Recording Adverse Events  
Eliciting Adverse Events  
The patient and legal guardian, if applicable, should be asked about medically relevant changes 
in the patient’s  health since the last visit.  The patient and legal guardian, if applicable, should 
also be asked if the patient  has been hospitalized, had any accidents , used any new medications, 
Clinical Study Protocol ALN -GO1 -003 lumasiran  
Amendment  3, 06 May  2020 
Alnylam Pharmaceuticals  Confidential  58 or changed concomitant medication routines (both prescription and over-the-counter ).  In 
addition to patient observations, AEs will be documented from any clinically relevant laboratory 
findings, physical examination findings, EC G changes, or other findings that are relevant to 
patient safety.    
Recording Adverse Events  
The Investigator is responsible for recording non -serious AEs that are observed or reported by 
the patient after administration of the first dose of study drug reg ardless of their relationship to 
study drug through the end of study.  Non -serious AEs will be followed until the end of study.  
The Investigator is responsible for recording SAEs that are observed or reported by the patient 
after the time when the informe d consent is signed regardless of their relationship to study drug 
through the end of study.  SAEs will be followed until satisfactory resolution, until baseline level 
is reached, or until the SAE is considered by the Investigator to be chronic or the pati ent is 
stable, as appropriate.  
All AEs must be recorded in the source records for the clinical study center and in the eCRF for 
the patient, whether or not they are considered to be drug -related.  Each AE must be described in 
detail:  onset time and date, description of event, severity, relationship to study drug, action 
taken, and outcome (including time and date of resolution, if applicable).  
For SAEs, record the event(s) in both the eCRF and the SAE form.  
6.5.7.3.  Reporting Adverse Events of Clinical Interest to Sponsor/Designee  
For AEs that are considered AEs of clinical interest (Section  6.5.7.1 ), the Sponsor or its designee 
should be notified within 24 ho urs using a supplemental AEs of Clinical Interest eCRF.  
Additional clinical and laboratory information may be collected.  Refer to CRF completion 
guidelines for details on reporting events in the supplemental AEs of Clinical Interest  eCRF.   
For all ISRs,  the Investigator, or delegate, should submit a supplemental ISR eCRF, recording 
additional information (eg, descriptions, onset and resolution date, severity, treatment given, 
event outcome).  
6.5.7.4.  Serious Adverse Events Require Immediate Reporting to Sponsor/D esignee  
An assessment of the seriousness of each AE will be made by the Investigator.  Any AE and 
laboratory abnormality that meets the SAE criteria in Section  6.5.7 .1 must be reported to the 
Sponsor or designee within 24 hours from the time that clinical study center staff first learns of 
the event.  All SAEs must be reported regardless of the relationship to study drug.  
The initial report should incl ude at least the following information:  
• Patient’s study number  
• Description and date of onset of the event  
• Criterion for serious  
• Preliminary assignment of relationship to study drug, and  
• Investigator/site information  
Clinical Study Protocol ALN -GO1 -003 lumasiran  
Amendment  3, 06 May  2020 
Alnylam Pharmaceuticals  Confidential  59 To report the SAE, complete the SAE form .  Within 24 hours of receipt of follow -up 
information, the Investigator must update the SAE form.  SAEs must be reported using the 
contact information provided in the Study Manual.  
Appropriate remedial measures should be taken by the Investigator using hi s/her best medical 
judgment to treat the SAE.  These measures and the patient’s response to these measures should 
be recorded.  All SAEs, regardless of relationship to study drug, will be followed by the 
Investigator until satisfactory resolution or the In vestigator deems the SAE to be chronic or 
stable.  Clinical, laboratory, and diagnostic measures should be employed by the Investigator as 
needed to adequately determine the etiology of the event.  
6.5.7.5.  Sponsor Safety Reporting to Regulatory Authorities  
The Spon sor or its representative will report certain study events in an expedited manner to the 
Food and Drug Administration, the European Medicines Agency’s EudraVigilance electronic 
system according to Directive 2001/20/EC, and to all country Regulatory Authori ties where the 
study is being conducted, according to local applicable regulations.  
6.5.7.6.  Serious Adverse Event Notification to the Institutional Review 
Board/Independent Ethics Committee  
Suspected unexpected serious adverse reactions (SUSARs) will be reported t o the IRB/IEC per 
their institutional policy by the Investigator or Sponsor (or Sponsor designee) according to 
country requirements.  Copies of each report and documentation of IRB/IEC notification and 
acknowledgement of receipt will be kept in the Investi gator’s study file.  
6.5.7.7.  Pregnancy Reporting  
If a female patient becomes pregnant during the study through study completion , the Investigator 
must report the pregnancy to the Sponsor or designee within 24  hours of being notified of the 
pregnancy.  Details of th e pregnancy will be recorded on the pregnancy reporting form.  The 
patient should receive any necessary counseling regarding the risks of continuing the pregnancy, 
the possible effects on the fetus, and be counseled to not breastfeed for 90 days after the last dose 
of study drug.  
The pregnancy should be followed by the Investigator until completion.  At the completion of the 
pregnancy, the Investigator will document the outcome of the pregnancy.  If the outcome of the 
pregnancy results in a postpartum compl ication, spontaneous abortion, stillbirth, neonatal death, 
or congenital anomaly, then the Investigator should follow the procedures for reporting an SAE 
as outlined in Section 6.5.7.4 . 
6.5.7.8.  Overdose Reporting  
An overdose is defined as any dose administered to or taken by a patient (accidentally or 
intentionally) that exceeds the highest daily dose, or is at a higher frequency, than included in the 
protocol.  The investigator will decide whether a dose is to be considered an overdose, in 
consulta tion with the Sponsor.  In the event of an overdose, the actual dose administered  must be 
recorded in the eCRF.  
Clinical Study Protocol ALN -GO1 -003 lumasiran  
Amendment  3, 06 May  2020 
Alnylam Pharmaceuticals  Confidential  60 All reports of overdose (with or without an A E) must be reported within 24  hours to the Sponsor 
or designee.  
6.5.8.  COVID -19 Data Collection  
Information on the coronavirus disease  2019 (COVID -19) infection status of the patient, if 
known, and other information on the impact of the COVID -19 pandemic on the patient's 
participation in the study will be collected.  
6.6. Biomarkers, DNA Genotyping, and Biospecimen Repository  
Alnylam’s RNAi therapeutics platform permits the highly specific targeting of investigational 
therapies based on genetic sequence.  It is possibl e that variations in the target genetic sequence 
will result in variations in drug effect.  
More generally, genetic variations may account for the well -described heterogeneous 
manifestations of disease in patients with PH1, as well as their responses to tre atment.  
To permit exploratory investigations and the application of novel approaches to bioanalyses that 
may further elucidate the outcomes of this study, or potentially advance understanding of the 
safety, mechanism of action, and/or efficacy of lumasiran , a set of biological specimens will be 
collected at the timepoints indicated in the Schedule of Assessments  (Table  1). 
These specimens will be securel y stored in a central biorepository for up to 10 years following 
the completion of this clinical study (ie, last patient last visit), or as per local regulations.  After 
10 years have elapsed, samples will be destroyed.  
Where allowed per local regulations,  ethics committee (IRB/EC) approval, and patient consent 
(and assent, where applicable), the samples will be collected as part of this study.  Potential 
exploratory investigations  may include  DNA, RNA or biochemical metabolite assessments as 
they relate to  disease progression, efficacy or safety.  
Details regarding the collection, processing, storage, and shipping of the samples will be 
provided in the Laboratory Manual.  
Exploratory analysis of these biospecimens will be performed by Alnylam Pharmaceuticals  or its 
designees.  
When biobanking is permitted by local regulation, patients/subjects will be advised during the 
informed consent process of these biobanking details and the potential for exploratory 
investigation of their samples.  
6.7. Quality of Life (QOL)  
QOL questionnaires will be used to evaluate overall health status and quality of life at the 
timepoints listed in Table  1 and Table  2.  During periods of time when the COVID -19 pandemic 
impedes the ability of patients to travel to the study site,  the KDQOL, PedsQL, and the EQ -5D 
questionnaires can be c ompleted up to 4  months after the intended time point.    
The age of the patient at screening will determine which age -specific questionnaires will be 
utilized for the duration of the study.   
QOL assessments include the following:  
Clinical Study Protocol ALN -GO1 -003 lumasiran  
Amendment  3, 06 May  2020 
Alnylam Pharmaceuticals  Confidential  61 • KDQOL, specifically the K DQO L-36 for patients  ≥18 years of age at screening , and 
the PedsQL, including the generic and ESRD modules  (parent and/or self -report 
versions)  [Salido -Guadarrama 2014 ] for patients <18  years of age at screening .  
• EQ-5D: a standardized instrument consisting of a questionnaire and a visual analog 
scale pertaining to 5 dimensions.  Scoring of the questionnaire is based on degrees of 
disability.  Scoring of the visual analog scale is based on a visual scale ranging from 0 
(worst imaginable health state) to 100 (best imaginable health state).  Higher scores 
indicate better health status.  The EQ -5D-5L questionnaire will  be utilized in patients 
≥18 years of age at screening, and the EQ -5D-Y questionnaire will be utilized in 
patients <18  years of age at screening, where available .[Herdman 2011 ] 
6.8. Patient and Caregiver Experience Survey s 
The patient and caregiver experience survey s assess patients’ experience living with PH1, 
including their experience with PH1 treatments, as well as the effect of PH1 on patients’ 
caregivers .  These survey s will be completed at the time points specified in the Schedules of 
Assessment ( Table  1 and Table  2) and each take approximately 10  minutes t o complete.   During 
periods of time when the COVID -19 pandemic impedes the ability  of patients to travel to the 
study site,  the patient  and caregiver experience surveys  can be completed up to 4  months after 
the intended time point.  
For the Patient Experience Survey, patients ≥1 3 years of age at screening will complete the 
survey themselves if they are able.  If the patient is unable to complete the Patient Experience 
Survey  alone, their caregiver or site staff  may complete the survey for the  patient.   If the patient 
is <1 3 years of age at screening, a caregiver will complete  the Patient Experience Survey  on 
behalf of the patient for as long as the patient remains under the legal age of consent . 
Additionally, for patients under legal age of co nsent at the time of screening, their caregiver will 
also be asked to complete the Caregiver Experience Survey. For patients who reach the legal age 
of consent per local regulations  during the study, caregivers will be encouraged to continue 
completing the survey, but are not required to do so.   
6.9. Patient and Caregiver Impact Questionnaire  
The patient and caregiver impact questionnaire will be used to assess impacts of PH1 on the 
patie nts’ lives, including their need to relocate/travel to receive treatment, the number and type 
of healthcare providers they use, and their ability to work and/or go to school.  The questionnaire 
will also assess the impact on caregivers’ employment.  This questionnaire will be completed at 
the time points specified in the Schedules of Assessment ( Table  1 and Table  2) and takes 
approximately 10  to 12 minutes to complete.  During periods of time when the COVID -19 
pandemic impedes the ability of patients to travel to the study site , the patient and caregiver 
impact questionnaire s can be completed up to 4  months after the intended time point .  
Patients ≥1 3 years of age at screening will complete the questionnaire themselves if they are 
able.  If the patient is unable to complete the survey alone, their  caregiver or site staff  may 
complete the survey on the patient’s behalf.  If the patient is <1 3 years of age at screening, a 
caregiver will complete the questionnaire  on behalf of the patient.  For patients who reach  the 
legal age of consent per local reg ulations during the study, and whose caregivers had previously 
Clinical Study Protocol ALN -GO1 -003 lumasiran  
Amendment  3, 06 May  2020 
Alnylam Pharmaceuticals  Confidential  62 completed the Patient Impact Questionnaire on their behalf, caregivers will be encouraged to 
continue completing the questionnaire , but are not required to do so.  
6.10. Healthcare Resource Utilization  
Healthcare resource utilization will be assessed using patient -reported information related to 
hospitalizations, urgent healthcare visits, procedures and surgeries.    
7. STATISTICS  
A Statistical Analysis Plan (SAP) will be finalized prior to database lock.   The plan will detail 
the implementation of the statistical analyses in accordance with the principle features stated in 
the protocol.  
7.1. Determination of Sample Size  
The planned enrollment for the study is 30 patients.  
Patients will be random ized 2:1 to receive lumasiran or placebo, respectively. Assuming the 
mean percent reduction from baseline to Month 6 in 24 -hour urinary oxalate corrected for body 
surface area (BSA) is 17% in the placebo arm and the standard deviation in both arms is 25%, 
24 patients will provide 90% power to detect a treatment difference of 37% at a 2 -sided 5% 
significance level (ie, 54% reduction in the lumasiran arm).  To account for potential drop -outs, 
30 patients are planned to be enrolled in the study.  
7.2. Statistical Me thodology  
The statistical and analytical plans presented below are brief summaries of planned analyses.  
More complete plans will be detailed in the statistical analysis plan (SAP).  Changes to the 
methods described in the final SAP will be described and j ustified as needed in the clinical study 
report.  For information on study endpoints, see  Section  2. 
Additional data summaries to help understand any impact of COVID -19 on efficacy and safety 
assessments will be outlined in the SAP.   
7.2.1.  Populations to be Analyzed  
The populations (analysis sets) are defined as follows:  
• Full Analysis Set (FAS):  All randomized patients who received any amount of study 
drug.  Patients will be analyzed according to the treatment to which they were 
randomized.   
• Per-protocol (PP) Set: All randomized patients who received any amount of study 
drug, had baseline and at least one post -baseline 24 -hour urinary oxalate, and did not 
experience any major protocol deviations that may impact the efficacy results  within 
the 6 -month double -blinded period . Patients will be analyzed according to the 
randomized treatment arms.  
• Safety Analysis Set:  All patients who received any amount a  of stud y drug. Patients 
will be analyzed according to the treatment actually received.  
Clinical Study Protocol ALN -GO1 -003 lumasiran  
Amendment  3, 06 May  2020 
Alnylam Pharmaceuticals  Confidential  63 • PK Analysis Set:  All patients who received at any amount of study drug and have at 
least 1 PK concentration measurement.  
• All Lumasiran Treated Set: All patients who received a ny amount of lumasiran 
including patients who took lumasiran during the 6 -month double -blinded period and 
patients who initially took placebo during the 6 -month double -blinded period and 
then switched to lumasiran during the extension period.  
The primary p opulation used to evaluate efficacy will be the Full Analysis Set for the primary 
endpoint and secondary endpoints during the double -blind period.  Safety during the double -
blind period will be analyzed using the Safety Analysis Set.  The PK Analysis Set w ill be used to 
evaluate the PK endpoints.  The All Lumasiran Treated Set will be used to summarize the long -
term efficacy and safety of lumasiran . 
7.2.2.  Examination of Subgroups  
Subgroup analyses may be conducted for selected endpoints.  Detailed methodology wil l be 
provided in the SAP.  
7.2.3.  Handling of Missing Data  
Every effort will be made to minimize the amount of missing data in the study, particularly for 
the 24 -hour urinary oxalate assessments.  Details will be provided in the SAP.  
7.2.4.  Baseline Evaluations  
Demograph ics and other disease -specific baseline characteristics will be summarized 
descriptively by treatment arm and overall for the FAS and Safety Analysis Set.  
7.2.5.  Efficacy Analyses  
7.2.5.1.  Primary Endpoint  
The primary endpoint is to compare the percent change from baseline to Month 6 in 24 -hour 
urinary oxalate corrected for BSA between the treatment groups in the Full Analysis Set.  The 
analysis will be performed using a mixed -effect model for repeated measures (MMRM) 
approach.  The outcome variable is percent chang e from baseline in urinary oxalate corrected for 
BSA.  The model includes baseline value as covariate and fixed effect terms including treatment 
arm and visit (Months 3, 4, 5, 6).  The treatment estimates from this model will represent an 
average percent c hange from baseline of 24 -hour urinary oxalate excretion across months 3 
through 6 at which the treatment effect is expected to have reached steady state.  Furthermore, 
given the variability of 24 -hour urinary oxalate, averaging the values across these vis its will 
yield stable treatment estimates.  
Baseline and Month  6 urinary oxalate values are planned to be collected in triplicate (minimum 
requirement of duplicate) and the calculated median of valid collections during each time period 
(visit) will be used in the analysis. BSA will be calculated using the Mosteller formula.  
Sensitivity analyses will be conducted to assess the robustness of the estimates and will be 
detailed in the SAP.  
Clinical Study Protocol ALN -GO1 -003 lumasiran  
Amendment  3, 06 May  2020 
Alnylam Pharmaceuticals  Confidential  64 A patient is considered to have completed the primary outcome measure at the time of 
completion of the Month 6 assessments.  
7.2.5.2.  Secondary Endpoints  
To control the overall type I error, these secondary endpoints will be tested in the following 
hierarchical order:  
• Absolute change in 24 -hour urinary oxalate corrected for BSA from base line to Month 6  
• Change in 24 -hour urinary oxalate:creatinine ratio (value/ULN) from baseline to Month 6  
• Proportion of patients with 24 -hour urinary oxalate level at or below 1.5  x ULN at Month 6  
• Proportion of patients with 24 -hour urinary oxalate level at or below ULN at Month 6  
• Percent change in plasma oxalate from baseline to Month 6  
• Absolute change in plasma oxalate from baseline to Month 6  
Continuous endpoints will be analyzed using an MMRM approach similar to the one described 
for the primary endpoint.   Binary endpoints will be analyzed using the Cochran -Mantel -Haenszel 
test stratified by baseline urinary oxalate. The odds ratio and the differences in proportions with 
corresponding 95% confidence will also be summarized.  
Secondary endpoints assessed bey ond Month 6 will be summarized descriptively. Change in 
eGFR over time will also be summarized descriptively . 
7.2.5.3.  Exploratory Endpoints  
Details will be described in the SAP.  
7.2.6.  Pharmacodynamic Analysis  
Analysis of the PD parameters are specified in Section  7.2.5.2 .  Any PD parameters not already 
prespecified for testing will be summarized descriptively . 
7.2.7.  Pharmacokinetic Analysis  
Population pharmacokinetic analysis  will be performed to describe the plasma concentration 
profiles of lumasiran. The impact of relevant patient covariates such as age, weight, race, gender, 
hepatic impairment, and renal impairment on the PK of lumasiran will be assessed using 
population PK  approach.  
For patients enrolled in East Asian centers with 24 -hour PK collection, pharmacokinetic analyses 
of plasma and urine will be conducted using noncompartmental methods.  Plasma 
pharmacokinetic parameters including, but will not be limited to:  max imum plasma 
concentration (C max), time to maximum plasma concentration (t max), elimination half -life (t ½β), 
area under the concentration -time curve (AUC), apparent clearance (CL/F), and apparent volume 
of distribution (V/F) will be determine using noncompa rtmental approach.  Other parameters 
may be calculated, if deemed necessary.  In addition, relevant urine PK parameters will be 
calculated using 24 -hour urine PK profiles.   
Clinical Study Protocol ALN -GO1 -003 lumasiran  
Amendment  3, 06 May  2020 
Alnylam Pharmaceuticals  Confidential  65 7.2.8.  Safety Analyses  
The primary parameter is the frequency and seriousness  of AEs.  Saf ety parameters also include 
vital signs, ECGs, clinical laboratory assessments and physical exams.  The extent of exposure 
will also be summarized.  The primary summaries of the safety of lumasiran versus placebo will 
be based on safety parameters within t he 6-month double -blind treatment period, using the 
Safety Analysis Set.  Additional safety analyses will also be performed for the extension periods . 
Prior and concomitant medications will be coded using the World Health Organization (WHO) 
Drug Dictionary .  Results will be tabulated by Anatomical Therapeutic Chemical (ATC) 
Classification System and Preferred Term (PT) .  
Adverse events will be coded by the Medical Dictionary for Regulatory Activities (MedDRA).  
AEs, SAEs, related AEs, and AEs leading to discontinuation will be summarized by System 
Organ Class (SOC) and PT for each treatment arm.  By -patient listings will be provided for 
deaths, SAEs, and events leading to discontinuation of treatment.  
Descriptive statistics will be provided for clinical l aboratory data, ECG, and vital signs data.  
Laboratory shift tables from baseline to worst values will be presented.  
Other safety summaries will be presented as appropriate.  Further details will be specified in the 
SAP.  
7.2.9.  Immunogenicity Analyses  
ADA  results  will be summarized descriptively.  
7.2.10.  Other Analyses  
Other exploratory analyses will be detailed in the SAP .   
7.2.11.  Interim Analysis  
No interim analysis is planned.  
7.2.12.  Optional Additional Research  
Optional additional research may be conducted in the future on the biological samples and/or 
data collected during the study in accordance with the strict terms of the informed consent form 
(see Section  4.3.2 ). 
8. STUDY  ADMINISTRATION  
8.1. Ethical and Regulatory Considerations  
This study will be conducted in accordance with the protocol, all applicable regulatory 
requirements, and the current guidelines of Good Clinical Practice (GCP).  Compliance with 
GCP provides public ass urance that the rights, safety, and well -being of study patients are 
protected consistent with the principles that have their origin in the Declaration of Helsinki.  
Clinical Study Protocol ALN -GO1 -003 lumasiran  
Amendment  3, 06 May  2020 
Alnylam Pharmaceuticals  Confidential  66 8.1.1.  Informed Consent  
The Investigator will ensure that the patient/legal guardian is given full  and adequate oral and 
written information about the nature, purpose, possible risk and benefit of the study.  
Patients/legal guardians must also be notified that they are free to discontinue from the study at 
any time.  The patient/legal guardian should b e given the opportunity to ask questions and 
allowed time to consider the information provided.  In the case of patients under the age of legal 
consent, legal guardian(s) must provide informed consent and the patient should provide assent 
per local regulat ions and institutional standards.  
The patient’s/legal guardian’s signed and dated informed consent (or assent, if applicable) must 
be obtained before conducting any study tests or procedures that are not part of routine care.   
When a patient under the age of legal consent who has been enrolled in the study reaches the 
legal age of consent, the investigator must obtain the patient's informed consent prior to 
performing any further research interventions and/or procedures involving that patient . 
The Investiga tor must maintain the original, signed ICF (assent form, if applicable).  A copy of 
the signed ICF (assent form, if applicable) must be given to the patient/legal guardian.   The 
Investigator will inform the patient/legal guardian if new information becomes  available that 
may be relevant to the patient’s/legal guardian’s willingness to continue participation in the 
study.  Communication of this information should be documented.  
8.1.2.  Ethical Review  
The study protocol, including the ICF ( and assent form, if applica ble), must be approved or given 
a favorable opinion in writing by an IRB or IEC, as appropriate.  The Investigator must submit 
written approval before he or she can enroll any patient into the study.  
The Investigator is responsible for informing the IRB or  IEC of any amendment to the protocol 
in accordance with local requirements.  In addition, the IRB or IEC must approve all patient 
materials for the study  (except those that support the need to remove an apparent immediate 
hazard to the patient) .  The prot ocol must be reapproved by the IRB or IEC upon receipt of  
amendments and annually, as local regulations require.  
Initial IRB approval of the protocol, and all materials approved by the IRB for this study 
including the patient consent form and assent form, as applica ble per institutional standards  and 
recruitment materials must be maintained by the Investigator and made available for inspection.  
The Investigator will submit reports of SAEs as outlined in Section  6.5.6.4 .  In addition, the 
Investigator agrees to submit progress reports to the IRB or IEC per their local reporting 
requirements, or at least annually and at the conclusion of the study.  The r eports will be made 
available to the Sponsor or designee.  
Any communications from regulatory agencies, IRBs, or IECs in regard to inspections, other 
studies that impact this protocol or the qualifications of study personnel should be promptly 
reported to t he Sponsor or its designee.  
The Investigator is also responsible for providing the IRB with reports of any reportable serious 
adverse drug reactions from any other study conducted with the study drug.  The Sponsor or 
designee will provide this information to the Investigator.  
Clinical Study Protocol ALN -GO1 -003 lumasiran  
Amendment  3, 06 May  2020 
Alnylam Pharmaceuticals  Confidential  67 Major changes in this research activity, except those to remove an apparent immediate hazard to 
the patient, must be reviewed and approved by the Sponsor and the IRB or IEC that approved the 
study.  Amendments to the protocol must be s ubmitted in writing to the Investigator’s IRB or 
IEC and the Regulatory Authority for approval before patients are randomized  under the 
amended protocol, and patients /legal guardian  must be re -consented to the most current version 
of the ICF ( and assent fo rm, as applicable).  
8.1.3.  Serious Breach of Protocol  
Investigators must notify the medical monitor within 24 hours of becoming aware of a serious 
breach of the protocol.  A serious breach is a breach that is likely to affect to a significant degree 
the safety an d rights of a study participant , or the reliability and robustness of the data generated 
in the clinical trial.  
8.1.4.  Study Documentation, Confidentiality, and Records Retention  
All documentation relating to the study should be retained for 2 years after the last approval in an 
ICH territory or as locally required, whichever is longer.  If it becomes necessary for the 
Sponsor, the Sponsor’s designee, applicable IRB/IEC, or applica ble regulatory authorities to 
review or audit any documentation relating to the study, the Investigator must permit direct 
access to all source documents/data.  Records will not be destroyed without informing the 
Sponsor in writing and giving the Sponsor t he opportunity to store the records for a longer period 
of time at the Sponsor’s expense.   
The Investigator must ensure that the patients’ confidentiality will be maintained.  On the eCRFs 
or other documents submitted to the Sponsor or designees, patients  should not be identified by 
their names, but by the assigned patient number or code.  If patient names are included on copies 
of documents submitted to the Sponsor or designees, the names will be obliterated and the 
assigned patient number added to the do cument.  Documents not for submission to the Sponsor 
(eg, signed ICFs) should be maintained by the Investigator in strict confidence.  
The Investigator must treat all of the information related to the study and the compiled data as 
confidential, whose use i s for the purpose of conducting the study.  The Sponsor must approve 
any transfer of information not directly involved in the study.  
To comply with local and/or regional regulations, this clinical study may be registered and study 
results may be posted on public registries, such as ClinicalTrials.gov.  
8.1.5.  End of Study  
The end of study is defined as the last patient last visit.  
8.1.6.  Termination of the Clinical Study or Site Closure  
The Sponsor, or designee, reserves the right to terminate the study or a clinical stud y site at any 
time.  Conditions that may warrant this action may include, but are not limited to:  
• The discovery of an unexpected, serious, or unacceptable risk to patients participating 
in the study  
Clinical Study Protocol ALN -GO1 -003 lumasiran  
Amendment  3, 06 May  2020 
Alnylam Pharmaceuticals  Confidential  68 • Failure of the Investigator to comply with the protocol, the requirements of the 
IRB/IEC or local health authorities, the Sponsor's procedures, or GCP guidelines  
• Inadequate recruitment of participants by the Investigator  
• The decision on the part of the Sponsor to suspend or discontinue treatment with the 
study d rug 
Should the study be terminated, and/or the site closed for whatever reason, all documentation and 
study drug pertaining to the study must be returned to the Sponsor or its representative, and the 
Investigators, IEC /IRB  and Regulatory Authorities will b e promptly informed of the termination 
and the reason for the decision.  The Investigator should promptly inform the patients and assure 
appropriate therapy and follow -up. 
8.2. Data Quality Control and Quality Assurance  
8.2.1.  Data Handling  
Study data must be recorded  on CRFs (paper and/or electronic) provided by the Sponsor or 
designee on behalf of the Sponsor.  Case report forms must be completed only by persons 
designated by the Investigator.  If eCRFs are used, study data must be entered by trained site 
personnel w ith access to a valid and secure eCRF system.  All data entered into the eCRF must 
also be available in the source documents.  Corrections on paper CRFs must be made so as to not 
obliterate the original data and must be initialed and dated by the person wh o made the 
correction.  
8.2.2.  Study Monitoring  
The Monitor, as a representative of the Sponsor, has an obligation to closely follow the study 
conduct at the site.  The monitor will visit the Investigator and clinical study center periodically 
and will maintain fr equent telephone and written contact.  The monitor will maintain current 
personal knowledge of the study through observation, review of study records and source 
documentation, and discussion of the conduct of the study with the Investigator and staff.  
The monitor will review source documents, systems and CRFs to ensure overall quality and 
completeness of the data and to confirm study procedures are complied with the requirements in 
the study protocol accurately. The Sponsor, or its designee, will be allowed  to conduct site visits 
to the investigation facilities for the purpose of monitoring any aspect of the study.  The 
Investigator agrees to allow the monitor to inspect the drug storage area, study drug stocks, drug 
accountability records, patient charts an d study source documents, site standard operating 
procedures and training records, and other records relative to study conduct.  
8.2.3.  Audits and Inspections  
Periodically, the Sponsor or its authorized representatives audit clinical investigative sites as an 
independent review of core trial processes and documents to determine whether these activities 
were conducted, and data were recorded, analyzed, and accurately reported according to the 
protocol, GCP guidelines of the ICH, and any applicable regulatory require ments.  A regulatory 
authority, an IEC or an IRB may visit the site to perform audits or inspections, including source 
Clinical Study Protocol ALN -GO1 -003 lumasiran  
Amendment  3, 06 May  2020 
Alnylam Pharmaceuticals  Confidential  69 data verification.  The Investigator should contact the Sponsor, or its designee, immediately if 
contacted by a regulatory agency, an IEC  or an IRB about an inspection.  
8.3. Publication Policy  
It is intended that after completion of the study, the data are to be submitted for publication in a 
scientific journal and/or for reporting at a scientific meeting.   A copy of any proposed 
publication (eg , manuscript, abstracts, oral/slide presentations, book chapters) based on this 
study, must be provided and confirmed received at the Sponsor at least 30 days before its 
submission.  The Clinical Trial Agreement among the institution, Investigator, and Aln ylam will 
detail the procedures for Alnylam’s review of publications.  
Authorship of any publications resulting from this study will be determined on the basis of the 
Uniform Requirement for Manuscripts Submitted to Biomedical Journals (International 
Commit tee of Medical Journal Editors).  
 
Clinical Study Protocol ALN -GO1 -003 lumasiran  
Amendment  3, 06 May  2020 
Alnylam Pharmaceuticals  Confidential  70 9. LIST OF REFERENCES   
Al-Eisa AA, Samhan M,Naseef M. End -stage renal disease in Kuwaiti children: an 8 -year 
experience. Transplant Proc. 2004 Jul -Aug;36(6):1788 -91. 
Boualla L, Tajir M, Oulahiane N, Lyahyai J, Laarabi FZ, Chafai Elalaoui S, et al. AGXT Gene 
Mutations and Prevalence of Primary Hyperoxaluria Type 1 in Moroccan Population. Genet Test 
Mol Biomarkers. 2015 Sep 18.  
Cochat P,Rumsby G. Primary hyperoxaluria. N Engl J Med. 2013 Aug 15;369(7):649 -58. 
Danpure CJ. Primary Hyperoxaluria. In: Beaudet AL, editor. The Online Metabolic and 
Molecular Bases of Inherited Disease. New York, NY: The McGraw -Hill Companies, Inc.; 2014.  
Feinstein Institute. The Feinstein Institute for Medical Research.  Human Subject Protection 
Program Guidance Document:  Maximum Blood Draw Limits. 2013.  
Frishberg Y, Rinat C, Shalata A, Khatib I, Feinstein S, Becker -Cohen R, et al. Intra -familial 
clinical heterogeneity: absence of genotype -phenotype correlation in primary hyperoxaluria  type 
1 in Israel. Am J Nephrol. 2005 May -Jun;25(3):269 -75. 
Harambat J, Fargue S, Acquaviva C, Gagnadoux MF, Janssen F, Liutkus A, et al. Genotype -
phenotype correlation in primary hyperoxaluria type 1: the p.Gly170Arg AGXT mutation is 
associated with a bet ter outcome. Kidney Int. 2010 Mar;77(5):443 -9. 
Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and 
preliminary testing of the new five -level version of EQ -5D (EQ -5D-5L). Qual Life Res. 2011 
Dec;20(10):1727 -36. 
Hopp K, Cogal AG,  Bergstralh EJ, Seide BM, Olson JB, Meek AM, et al. Phenotype -Genotype 
Correlations and Estimated Carrier Frequencies of Primary Hyperoxaluria. J Am Soc Nephrol. 
2015 Feb 2.  
Hoppe B. Evidence of true genotype -phenotype correlation in primary hyperoxaluria type 1. 
Kidney Int. 2010 Mar;77(5):383 -5. 
Hoppe B, Danpure CJ, Rumsby G, Fryer P, Jennings PR, Blau N, et al. A vertical 
(pseudodominant) pattern of inheritance in the autosomal recessive disease primary 
hyperoxaluria type 1: lack of relationship between g enotype, enzymic phenotype, and disease 
severity. Am J Kidney Dis. 1997 Jan;29(1):36 -44. 
Kamoun A,Lakhoua R. End -stage renal disease of the Tunisian child: epidemiology, etiologies, 
and outcome. Pediatr Nephrol. 1996 Aug;10(4):479 -82. 
Levey AS, Stevens LA,  Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, et al. A new 
equation to estimate glomerular filtration rate. Ann Intern Med. 2009 May 5;150(9):604 -12. 
Liebow A, Li X, Racie T, Hettinger J, Bettencourt BR, Najafian N, et al. An Investigational 
RNAi Thera peutic Targeting Glycolate Oxidase Reduces Oxalate Production in Models of 
Primary Hyperoxaluria. J Am Soc Nephrol. 2017 Feb;28(2):494 -503. 
Lieske JC, Monico CG, Holmes WS, Bergstralh EJ, Slezak JM, Rohlinger AL, et al. 
International registry for primary h yperoxaluria. Am J Nephrol. 2005 May -Jun;25(3):290 -6. 
Clinical Study Protocol ALN -GO1 -003 lumasiran  
Amendment  3, 06 May  2020 
Alnylam Pharmaceuticals  Confidential  71 Mandrile G, van Woerden CS, Berchialla P, Beck BB, Acquaviva Bourdain C, Hulton SA, et al. 
Data from a large European study indicate that the outcome of primary hyperoxaluria type 1 
correlates with the AGXT mutation type. Kidney Int. 2014 Dec;86(6):1197 -204. 
Salido -Guadarrama I, Romero -Cordoba S, Peralta -Zaragoza O, Hidalgo -Miranda A,Rodriguez -
Dorantes M. MicroRNAs transported by exosomes in body fluids as mediators of intercellular 
communication in canc er. Onco Targets Ther. 2014;7:1327 -38. 
Schwartz GJ, Munoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, et al. New equations to 
estimate GFR in children with CKD. J Am Soc Nephrol. 2009 Mar;20(3):629 -37. 
van der Hoeven SM, van Woerden CS,Groothoff JW. Prim ary hyperoxaluria type 1, a too often 
missed diagnosis and potentially treatable cause of end -stage renal disease in adults: results of 
the Dutch cohort. Nephrol Dial Transplant. 2012 Oct;27(10):3855 -62. 
van Woerden CS, Groothoff JW, Wanders RJ, Davin JC,W ijburg FA. Primary hyperoxaluria 
type 1 in The Netherlands: prevalence and outcome. Nephrol Dial Transplant. 2003 
Feb;18(2):273 -9. 
Williams EL, Acquaviva C, Amoroso A, Chevalier F, Coulter -Mackie M, Monico CG, et al. 
Primary hyperoxaluria type 1: update an d additional mutation analysis of the AGXT gene. Hum 
Mutat. 2009 Jun;30(6):910 -7. 
 
Clinical Study Protocol ALN -GO1 -003 lumasiran  
Amendment  3, 06 May  2020 
Alnylam Pharmaceuticals  Confidential  72 10. APPENDICES  
10.1. Formulae for Estimated Glomerular Filtration Rate Calculation  
Estimated glomerular filtration rate (eGFR; in mL/min/1.73m2) will be calculated from serum 
creatinine (SCr) based on the Modification of Diet in Renal Disease formula for patients 
≥18 years of age and the Schwartz Bedside Formula for patients <18 years of age.  
 
Modification of Diet in Renal Disease Formula [Levey 2009 ] 
• Conventional units  
− eGFR (mL/min/1.73m2) = 175 × (S Cr [mg/dL])-1.154 × (age)-0.203 × (0.742, if 
female), or ×  (1.212, if African American)  
• SI units  
− eGFR (mL/min/1.73m2) = 175 × (SCr [μmol/L]/88.4)-1.154 × (age)-0.203 × (0.742, if 
female), or × (1.212, if African American)  
 
Schwartz Bedside Formula [Schwartz 2009 ] 
• Conventional units  
− eGFR (mL/min/1.73 m2) = (0.413 × height [cm])/S Cr (mg/dL)  
• SI units  
− eGFR (mL/mi n/1.73 m2) = (36.2 × height [cm])/ SCr (µmol/L)  
  
Clinical Study Protocol ALN -GO1 -003 lumasiran  
Amendment  3, 06 May  2020 
Alnylam Pharmaceuticals  Confidential  73 10.2. Blood Volume Limits in Pediatric Patients  
The maximum blood volume, which will be collected from pediatric patients over the course of 
the study, will be based on age and weight and will not exceed those spe cified in Table  10, which 
was adapted from the Feinstein Institute for Medical Research Human Subject Protection 
Program Guidance Document.  
Table  10: Maximum Allowable Total Blood Volume Collection Chart  
Body 
Weight  Body 
Weight  Total blood 
volume  Maximum allowable 
volume in a 24 hour 
 Total volume collected 
in a 30 -day period  
2.5% of 
total blood 
volume  3% of total 
blood 
volume  5% of 
total blood 
volume  10% of 
total blood 
volume  
(kg) (lbs)  (mL)  (mL)  (mL)  (mL)  (mL)  
1 2.2 100 2.5 3 5 10 
2 4.4 200 5 6 10 20 
3 6.6 240 6 7.2 12 24 
4 8.8 320 8 9.6 16 32 
5 11 400 10 12 20 40 
6 13.2 480 12 14.4 24 48 
7 15.4 560 14 16.8 28 56 
8 17.6 640 16 19.2 32 64 
9 19.8 720 18 21.6 36 72 
10 22 800 20 24 40 80 
11-15 24-33 880-1200  22-30 26.4-36 44-60 88-120 
16-20 35-44 1280 -1600  32-40 38.4-48 64-80 128-160 
21-25 46-55 1680 -2000  42-50 50.4-60 64-100 168-200 
26-30 57-66 2080 -2400  52-60 62.4-72 104-120 208-240 
31-35 68-77 2480 -2800  62-70 74.4-84 124-140 248-280 
36-40 79-88 2880 -3200  72-80 86.4-96 144-160 288-320 
41-45 90-99 3280 -3600  82-90 98.4-108 164-180 328-360 
46-50 101-110 3680 -4000  92-100 110.4 -120 184-200 368-400 
51-55 112-121 4080 -4400  102-110 122.4 -132 204-220 408-440 
56-60 123-132 4480 -4800  112-120 134.4 -144 224-240 448-480 
61-65 134-143 4880 -5200  122-130 146.4 -156 244-260 488-520 
66-70 145-154 5280 -5600  132-140 158.4 -168 264-280 528-560 
71-75 156-165 5680 -6000  142-150 170.4 -180 284-300 568-600 
76-80 167-176 6080 -6400  152-160 182.4 -192 304-360 608-640 
81-85 178-187 6480 -6800  162-170 194.4 -204 324-340 648-680 
86-90 189-198 6880 -7200  172-180 206.4 -216 344-360 688-720 
91-95 200-209 7280 -7600  182-190 218.4 -228 364-380 728-760 
96-100 211-220 7680 -8000  192-200 230.4 -240 384-400 768-800 
Adapted from http://www.feinsteininstitute.org/wp -content/uploads/2013/02/Maximum -Blood -
Draw -Limits.pdf. [Feinstein Institute 2013 ]  
 
Clinical Study Protocol ALN -GO1 -003 ALN -GO1 ( lumasiran ) 
Amendment  3 Summary of Changes, 06 May  2020  
Alnylam Pharmaceuticals  Confidential  1 ALN -GO1 -003 PROTOCOL AMENDMENT  3  
SUMMARY OF CHANGES D ATED 06 MAY  2020  
ILLUMINATE -A: A Phase  3 Randomized, Double -Blind, Placebo Controlled Study with 
an Extended Dosing Period to Evaluate the Efficacy and Safety of Lumasiran in Children 
and Adults with Primary Hyperoxaluria Type  1 
1. RATIONALE FOR PROTOC OL AMENDMENT  
The primary purpose of this protocol amendment is to incorporate Urgent Safety Measures 
(USMs) that were communicated to  investigators in a Dear Investigator Letter dated 
02 April  2020 to assure the safety of study participants while minimizing risks to study integrity 
amid the coronavirus 2019 (COVID -19) pandemic.  These changes are in line with guidance 
from both the Euro pean Medicines Agency [EMA  2020 ] and the United States Food and Drug 
Administration [FDA  2020 ] on the conduct of clinical trials during the COVID -19 pandemic.   
The USMs are summarized in Section  1.1 and described in greater detail in Section  2.   
This protocol amendment also incorporates the changes that are not related to USMs.  After 
ongoing review and assessment of the safety data from studies conducted with lumasiran, 
modificati ons are designed to enhance patient safety and reduce patient burden regarding blood 
sampling.  These changes will not be implemented until appropriate Health Authority and Ethics 
Committee (EC) and/or Institutional Review Board (IRB) approval, if applicab le.  These changes 
are summarized in Section  1.2 and described in greater detail in Section  2. 
1.1. Notification of Urgent Safety Measures Due to the Impact of the 
COVID -19 Pandemic  
The USM modifications and new procedures are outlined below, and a detailed summary of the 
USMs is provided in  Table  1.  These measures were to be adopted immediately by the 
Investigator site as specified in the Dear Investigator Letter.  
• Lumasiran dosing outside the study center (expanded use of offsite admin istration)  
Following appropriate training on lumasiran administration, dosing will be permitted at a 
location other than the study center (eg, at home) by the patient/ caregiver at all time 
points under the oversight of the Investigator and following consul tation with the Medical 
Monitor.  This measure is intended to remain in effect only during periods of time when 
the COVID -19 pandemic impedes the ability of patients to travel to the study site and 
healthcare professionals to go to patients' homes for dosi ng.   
• Study visits  
Except for assessments with other specified timing requirements, study assessments can 
be performed within the expanded window of ±28  days (previously ±14  days) .  The 
expanded window for study visits is to ensure patient safety and to t he extent possible, 
maintain study integrity amid travel and other restrictions related to the COVID -19 
pandemic.  
Clinical Study Protocol ALN -GO1 -003 ALN -GO1 ( lumasiran ) 
Amendment  3 Summary of Changes, 06 May  2020  
Alnylam Pharmaceuticals  Confidential  2 • Kidney Disease Quality of Life Questionnaire (KDQOL), Pediatric Quality of Life 
Inventory (PedsQL), Euro Quality of Life Health State Profile Questionnaire 
(EQ-5D), the Patient/Caregiver Experience surveys , and Patient/Caregiver 
questionnaires .   
The KDQOL, PedsQL, and EQ -5D questionnaires, the patient  and c aregiver experience 
surveys, and the patient  and c aregiver impact questionnaires may be completed up to 
4 months after the intended time point . 
• Renal ultrasound and electrocardiogram (ECG) assessments  
Renal ultrasound and ECG assessments may be completed up to 7  months after the 
intended timepoint for visits at Month  12 and later to ensure patient safety and to the 
extent possible, maintain study integrity amid travel and other restrictions related to the 
COVID -19 pandemic .  This expansion of the ECG assessment window is supported by 
results of a clinical corrected QT interval ( QTc) assessment and nonclinical cardiac safety 
assessment of lumasiran, which demonstrated that lumasiran does not have QTc 
prolongation properties .  
• Physical examination  
If a visit is conducted offsite (eg, home), a body system assessment  may be performed in 
lieu of a physical examination . 
• Assessments required to be performed in the clinic (offsite assessments)  
Where applicable country and local regulations and infrastructure allow for home 
healthcare, healthcare may take place at a location other than the cli nical trial site to 
perform study assessments, which may include pregnancy testing (urine or serum), 
clinical laboratory assessments, urine collections, DNA testing, a body system 
assessment, vital signs, body weight, height, PK and PD blood collection, bl ood 
collection for vitamin  B6 levels, ADA and exploratory analyses (blood and urine) 
assessments, at all timepoints as specified in the Schedule of Assessments . 
• Assessment of adverse events (AEs), concomitant medications, renal stone events, 
and healthcare  utilization (remote contact permitted)  
In situations where a study visit is unable to be completed (either at the site or offsite by a 
healthcare professional), the Investigator (or delegate) will verbally contact the patient 
within the study visit windo w to assess AEs , concomitant medication  use, renal stone 
events , and healthcare utilization , to ensure timely collection of patient data.  
• Pharmacokinetic assessments  
Blood sample s for PK assessment should continue to be collected at 4  hours postdose  as 
specified in the Schedule of Assessments .  Blood samples for PK assessment  at 24 hours 
postdose are to be collected only if feasible  during periods of time when the COVID -19 
pandemic impedes the ability of patients to travel to the study site and healthcare 
professionals to go to patients' homes . 
• Impact of COVID -19 (collection of information)  
Clinical Study Protocol ALN -GO1 -003 ALN -GO1 ( lumasiran ) 
Amendment  3 Summary of Changes, 06 May  2020  
Alnylam Pharmaceuticals  Confidential  3 Information related to the impact of the COVID -19 pandemic on patient participation in 
the study will be collected for each patient.  Additional information  regarding collection 
of this information, including completion of a new case report form specific to 
COVID -19, will be provided separately . 
This change is implemented to enable an alysis of the impact of the COVID -19 global 
pandemic on clinical trial data.  
• Updates to study administration text  
Text was updated to provide clarification of Investigator responsibilities regarding  
communication of new study information to patients and IRB/IECs . 
1.2. Changes Not Related to Urgent Safety Measures  
Additional changes to study conduct (outlined below) will not be implemented until appropriate 
HA and EC/IRB approval.  The removal of the requirement for measurement of coagulation 
parameters as part of routine surveillance laboratory assessments, and also for following serial  
coagulation parameters in the case of asymptomatic patients with confirmed isolated elevations 
of alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) >3 × upper limit of 
normal (ULN), with no alternative cause identified .  Removing these  requirements mitigates 
patient burden regarding the volume of blood to be collected, which is particularly important for 
pediatric patients given the greater limits placed on blood volume collections.  No safety signal 
pertaining to coagulation has been i dentified to date in any clinical study conducted with 
lumasiran .  This amendment will also:  
• Remove the collection of blood samples to assess pyridoxine (Vitamin  B6) levels after 
Month  18 and after discontinuation of pyridoxine therapy.  After a patient discontinues 
pyridoxine therapy, measurement of pyridoxine is no longer medically indicated to verify 
medication compliance.   
A detailed summary of changes is provided in Table  2 of Section  2.  The following changes are 
not detailed:  administrative changes, changes associated with administrative letter s (between 
Amendments  2 and 3), and corrections to typographical errors, punctuation, grammar, 
abbreviations, and formatting.  
Clinical Study Protocol ALN -GO1 -003 ALN -GO1 ( lumasiran ) 
Amendment  3 Summary of Changes, 06 May  2020  
Alnylam Pharmaceuticals  Confidential  4 2. PROTOCOL AMENDMENT  3 DETAILED SUMMARY OF  CHANGES  
The primary section(s) of the protocol affected by the changes in Protocol Amendment  3 are indicated.  The corresponding text has 
been revised throughout the pr otocol.  Deleted text is indicated by strikeout ; added text is indicated by bold  font. 
Table  1: Urgent Safety Measures COVID -19-related Changes to be Adopted Immediately  
Purpose:  Expand the use of offsite administration to include lumasiran dosing by the patient or caregiver  and provide additional 
instructions on self -administration, and preparation, handling, and storage of the study drug . 
The primary change occurs in Section  5.2.2, Dose and Administration  
Revised text:  Study drug injections will be administered under the supervision of the Investigator  or healthcare professional .  The 
injection site may be marked and mapped for later observation.  The sites preferred site of injection may be  is the abdomen , Optional 
additional sites are the upper arms, or and thighs.  If a local reaction around the injection site occurs, photographs may be obtained.  
Detailed instructions for study drug administration are found in the Pharmacy Manual .   
From Month  1215 through the end of the study, study drug administration may be conducted at a location other than the study center  
(eg, home) by a home  healthcare professional with the oversight of the Investigator, where applicable country and local regulations 
and in frastructure allow  after consultation with the medical monitor .  However, continued study drug administration at the study 
center should be considered for patients who have ongoing study drug -related AEs, worsening injection site reactions with repeat 
dosing, or for anyone in the opinion of the Investigator who would benefit from clinical observation following dosing.   
If the patient is unable to come to the study site, and a visit by a healthcare professional is not possible due to circumsta nces 
related t o the COVID -19 pandemic, lumasiran may be administered by the patient or the caregiver under the oversight of the 
Investigator, and following consultation with the Medical Monitor, as allowed by applicable country and local regulations.  I n 
such cases, the  patient or caregiver must receive appropriate training on lumasiran administration prior to dosing.  This 
measure is intended to remain in effect only during periods of time when the COVID -19 pandemic impedes the ability of 
patients to travel to the study  site and healthcare professionals to go to the patient’s home for dosing .   
Additional details can be found in the Pharmacy Manual.   In addition, instructions and procedures related to administration of 
lumasiran  by a patient or caregiver will be provided in the Patient/Caregiver Storage and Administration Instructions . 
Sections also reflecting this change:   
• Table 1 and Table 2, Schedules of Assessment  
• Section 3.1, Summary of Study Design  
Clinical Study Protocol ALN -GO1 -003 ALN -GO1 ( lumasiran ) 
Amendment  3 Summary of Changes, 06 May  2020  
Alnylam Pharmaceuticals  Confidential  5 • Section  5.2.4 , Preparati on, Handling, and Storage  
• Section  5.4, Treatment Compliance  
• Section  6.5.6.2 , Pregnancy Testing  
Purpose:  Allow additional offsite assessments . 
The primary change occurs in Section  6, Study Assessments . 
Revised  text:  Where applicable country and local regulations and infrastructure allow for home healthcare, healthcare may 
take place at a location other than the clinical trial site to perform study assessments, which may include pregnancy testing 
(urine or serum),  clinical laboratory assessments, urine collections,  DNA testing , symptom directed physical examination / body 
system assessment, vital signs, body weight, height, PK and PD blood collection, blood collection for vitamin B6 levels, ADA 
and exploratory analyses (blood and urine) assessments, at all timepoints as specified in the Schedule of Assessments.  Study 
assessments for pregnancy test (urine or serum), clinical lab assessments, urine collection, and DNA testing may be conducted  at a 
location other than the s tudy center by a home healthcare professional, where applicable country and local regulations and 
infrastructure allow.  
Sections also reflecting this change:   
• Section  6.5.3 , Physical Examination  
Purpose:  Expand the study visit window.  
The primary change occurs in Table  2, Schedule of Assessments; Schedule of Assessments – Open Label Extension Period (After 
Month  9 through Year  5). 
Revised  text:  In Table  2, the visit window was changed to ±28  days (previously ±14 days) for all visits.  
Section also reflecting this change:   
• Table 3, Pharmacokinetic and ECG Assessment Time Points: All Sites except East Asian Sites, Footnote Notes  
Purpose:  Expand study assessment windows  for ECGs and renal ultrasound . 
The primary change occurs in Section  6.5.4, Electrocardiogram  
Revised text: During periods of time when the COVID -19 pandemic impedes the ability of patients to travel to the study site, 
ECG assessments may be completed up to 7  months after the intended timepoint for visits at Month  12 and la ter. 
Sections also reflecting this change:   
Clinical Study Protocol ALN -GO1 -003 ALN -GO1 ( lumasiran ) 
Amendment  3 Summary of Changes, 06 May  2020  
Alnylam Pharmaceuticals  Confidential  6 • Table 3, Pharmacokinetic and ECG Assessment Time Points: All Sites except East Asian Sites, Footnote Notes  
• Section  6.5.5 , Renal Ultrasound  
Purpose:  Expand the window for completion of QOL questionnaires, patient and caregiver experience surveys and patient and 
caregiver impact questionnaires.  
The primary change occurs in Section  6.7, Quality of Life (QOL) Questionnaires  
Revised text:  During periods of time when the COVID -19 pandemic impedes the ability of patients to travel to the study site,  
the KDQOL, PedsQL, and the EQ -5D questionnaires can be completed up to 4  months after the intended time point . 
Sections also reflecting this change:  
• Section  6.8, Patient and Caregiver Experience Survey  
• Section  6.9, Patient and Caregiver Impact Questionnaire  
Purpose:  Reduce required blood sample collection timepoints for PK assessments.  
The primary change occurs in Table  3, Pharmacokinetic and ECG Asse ssment Time Points: All Sites except East Asian Sites, 
Footnote Notes . 
Revise d text:  Blood samples for PK assessment may be collected at 24  hours postdose as feasible during periods of time when 
the COVID -19 pandemic impedes the ability of patients to tra vel to the study site and the healthcare professionals to go to the 
patients’ homes.  
Purpose:  Allow continu al assessments of AEs , concomitant medication use , renal stone events , and healthcare utilization  via remote 
contact . 
The primary change occurs in Table 1 and Table  2, Schedule s of Assessments  
Revised  text: In situations where a study visit is unable to be completed (either at the study site or offsite  by a healthcare 
professional), the Investigator (or delegate) will verbally contact the patient wi thin the study visit window to assess 
concomitant medication s, renal stone events, adverse events, and healthcare utilization . 
Purpose:  To clarify lost to follow -up if a patient misses a required study visit.  
The primary change occurs in Section 4.3.4, Lost to Follow -Up 
Revised text:  A patient will be considered lost to follow -up if the patient repeatedly fails to return for scheduled visits and is unable to 
be contacted by the clinical study center.  The following actions must be taken if a patient misses fails to return to the clinical for  a 
required study visit.  
Clinical Study Protocol ALN -GO1 -003 ALN -GO1 ( lumasiran ) 
Amendment  3 Summary of Changes, 06 May  2020  
Alnylam Pharmaceuticals  Confidential  7 Purpose:  Collect information related to the impact of the COVID -19 pandemic on patient participation in the study.  
The primary change occurs in Section  6.5.8, COVID -19 Data Collection  
Revised text:  Information on the coronavirus disease 2019 (COVID -19) infection status of the patient, if known, and other 
information on the impact of the COVID -19 pandemic on the patient's participation in the study will be collected.  
Section also reflecting th is change:   
• Section 7.2, Statistical Methodology  
Purpose:  Revise and update informed consent instructions  
The primary change occurs in Section  8.1.1, Informed Consent  
Revised text:  The Investigator will inform the patient/legal guardian if new information becomes available that may be 
relevant to the patient’s/legal guardian’s willingness to continue participation in the study.  Communication of this 
information should be documented.  
Purpose:  Revise and update ethical review instructions.  
The primary change occurs in Section  8.1.2, Ethical Review  
Revised text:  In addition, the IRB or IEC must approve all patient  material s for the study ( except those that support the need to 
remove an apparent immediate hazard to the patient ). 
 
Clinical Study Protocol ALN -GO1 -003 ALN -GO1 ( lumasiran ) 
Amendment  3 Summary of Changes, 06 May  2020  
Alnylam Pharmaceuticals  Confidential  8 Table  2: Changes Not Related to Urgent Safety Measures to be Implemented After Health Authority and Ethics 
Committee(EC)/Institutional Review Board (IRB) Approval, where applicable  
Purpose:  Remove the requirement f or measurement of pyridoxine after Month  18. 
The primary change occurs in Section  5.3, Concomitant Medications  
Revised  text: Patients should continue their current standard of care regimen, including hyperhydration, crystallization inhibitors, 
and/or pyridoxine therapy for the first 12  months of the study.  Standard of care treatment may be adjusted beginning at Month  12 in 
accordance with clinical judgement.  If pyridoxine therapy is discontinued, pyridoxine levels should be assessed for at least the next 2 
study visits.  
Sections also reflecting this change:  
• Table  2, Schedule of Assessments  
• Table  8, Clinical Laboratory Assessments , Footnotes  
Purpose:  Removes the requirement for measurement of coagulation parameters as part of routine surveillance lab oratory 
assessments .  
The primary change occurs in Section  6.5.6 Table  8, Clinical Laboratory Assessments  
Revised  text:  Coagulation:  Prothrombin time, Partial thromboplastin time, International normalized ratio.  
Section also reflecting this change:  
• Table 6, Monitoring and Dosing Rules for Asymptomatic Patients with Confirmed Isolated Elevations of ALT and/or AST 
>3× ULN, with No Alternative Cause Identified  
Purpose:  Expand  the window for obtaining body weight to 4 months (from 3  months ) before dosin g to calculate the study drug dose . 
The primary change occurs in Section  5.2.2, Dose and Administration  
Revised t ext: Body weight collected within 3 4 months prior to the study drug dose or the predose weight collected on the study visit 
day or dosing day will be used for dose calculations.  
Section also reflecting this change:  
• Section  6.5.2 , Weight and Height  
Clinical Study Protocol ALN -GO1 -003 ALN -GO1 ( lumasiran ) 
Amendment  3 Summary of Changes, 06 May  2020  
Alnylam Pharmaceuticals  Confidential  9 3. REFERENCES  
Guidance on the Management of Clinical Trials during the COVID -19 (Coronavirus) Pandemic, 
(20/03/2020; updated 27/03/2020; updated 28/04/2020). 
https://ec.europa.eu/health/sites/health/files/files/eudralex/vol -
10/guidanceclinicaltrials_covid19_en.pdf  
FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID -19 Pandemic: 
Guidance for Industry, Investigators, a nd Institutional Review Boards (03/2020; updated 
16/04/2020). https://www.fda.gov/regulatory -information/search -fda-guidance -documents/fda -
guidance -conduct -clinical -trials -medical -products -during -covid -19-pandemic  
 
Clinical S tudy Protocol ALN -GO1 -003 lumasiran  
Amendment 2 Summary of Changes, 19 March  2019  
 
Alnylam Pharmaceuticals  Confidential  1 ALN -GO1 -003 PROTOCOL AMENDMENT 2  
SUMMARY OF CHANGES DATED  19 MARCH  2019 
 
ILLUMINATE -A:  A Phase 3 Randomized, Double -Blind, Placebo -Controlled Study  
with an Extended Dosing Period to Evaluate the Efficacy and Safety of Lumasiran in 
Children and Adults with Primary Hyperoxaluria Type 1  
 
Rationale for Protocol Amendment  
The primary purpose for this protocol amendment is to broaden the patient population by 
allowing enrollment of patients with a glomerular filtration rate ≥30  mL/min/1.73  m2 and to 
align clinical objectives and endpoints across the Phase 3 program.   A summa ry of the changes is 
outlined below.  
The following inclusion criterion  has been modified:  
 Specify (to 2 decimals) the mean 24 -hour urinary oxalate excretion as ≥0.70 
mmol/24h/1.73m2. 
The following exclusion criterion  has been modified:  
 Change  the exclusion  threshold for the glomerular filtration rate from 
≤45 mL/min/1.73  m2 to <30  mL/min/1.73  m2. 
In addition, the following changes have been implemented for this study:  
 Clarif y that the Month 12 visit spans 2 days  in the Schedule of Assessments  for the 
Open Label Extension Period  (Table 2) . 
 Clarif y that a predose PK sample is taken on the day of dosing  in the PK assessment 
tables  (Table 3 and Table 4) . 
 Add a rationale for the dosing regimen in patients with eGFR ≥30 mL/min/1.73 m2. 
 Update the secondary and exploratory objectives and endpoin ts, including changing  
the evaluation of the long -term effects of lumasiran and plasma oxalate levels from 
exploratory to secondary objective s and endpoint s.   
 Update the blinding rules to accommodate site pharmacies with established polic ies 
that do not support masking the study drug during transfer from vial to syringe.  
 Clarify that additional liver function tests are performed when no alternative cause is 
identified . 
 Add that male patients may be required to use contrac eption (condom) in some 
countries, such as France, to comply with local requirements.  
 Clarify that specific study assessments may be conducted at a location other than the 
study center by a home healthcare professional . 
Clinical S tudy Protocol ALN -GO1 -003 lumasiran  
Amendment 2 Summary of Changes, 19 March  2019  
 
Alnylam Pharmaceuticals  Confidential  2  Add that patients may be rescreened per investigator judgment and after consultation 
with the Medical Monitor . 
 Specif y that pregnancy tests may be performed more frequently as per local 
requirements.  
 Clarify that if the relationship between an AE and the study drug is at least reasonably 
possible, it is considered “related” to the study drug.  
 Update the description of the quality of life questionnaires.  
 Update the description of the analysis populations, how missing data are handled, and 
descriptions of the primary and secondary endpoints  and analyses . 
 Update the description of the pharmacodynamic analysis . 
 Stipulate discontinuation criteria for the termination of the clinical trial or a clinical 
study site.  
 Remove that an Institution or Investigator must wait 18 months to submit a 
publication once the primary manuscript has been published since the number of 
months varies per local requirements and this information is specified in the  clinical 
trial agreement . 
A detailed summary of changes is provided in  Table  1.  Corrections to typographical errors, 
punctuation, grammar, abbreviations, and formatting (inclu ding administrative changes between  
protocol amendment 1  and p rotocol amendment 2) are not detailed . 
 
Clinical S tudy Protocol ALN -GO1 -003 lumasiran  
Amendment 2 Summary of Changes, 19 March  2019  
 
Alnylam Pharmaceuticals  Confidential  3 Table  1: Protocol Amendment  2 Detailed Summary of Changes  
The primary section(s) of the protocol affected by the changes in Protocol A mendment 2 are indicated.  Deleted text is indicated by 
strikeout ; added text is indicated by bold  font. 
Purpose: Clarify that the Month 12 visit span s 2 days. 
The change occurs in Table 2, Schedule of Assessments – Open Label Extension Period (After Month 9 through Year 5) ( bullet in “Notes”)  
Added:   Gray -shaded column indicate s the  visit where assessments span 2 days . 
Purpose: Clarif y that a predose PK sample is taken on the day of dosing.  
The change occurs in Table 3, Pharmacokinetic and Electrocardiogram Assessment Time Points: All Sites except East Asian Sites ( bullet in 
“Notes”)  
Added:   Predose samples are collected on the day of dosing.  
Sections also containing this change:  
 Table 4, Pharmacokinetic and Electrocardiogram Assessment Time Points: East Asian Sites  
Purpose:  Add a rationale for the dosing regimen in patients with eGFR  ≥30 mL/min/1.73 m2. 
The primary change occurs in 1. 4, Dose  Rational e 
Added : In patients with PH1, population PK/PD modeling demonstrated dose dependent oxalate reductions over the dose range (1.0 to 
6.0 mg/kg continuous once  monthly or once every 3 months SC administrations), with diminishing additional effect predicted 
with higher doses consistent with an asymptotic rather than linear relationship.  For a given dose, the PK/PD model indicated  
that monthly administration lead s to a more rapid decline in urinary oxalate levels relative to dosing every 3 months.  A 
combination of monthly dosing in a loading phase and then dosing every 3 months in a maintenance phase achieves the goals 
of rapid and consistent lowering of urinary oxalate to normal or near normal levels in PH1 patients.  Preclinical and clinical 
data indicate the renal pathway is a minor elimination route for lumasiran. Thus, renal impairment is not expected to 
influence systemic exposure, PD, and safety properties o f lumasiran, and no dose adjustments are needed based on 
renal functio n. Thus, a lumasiran dosing regimen of 3.0 mg/kg once monthly for 3 doses followed by 3.0 mg/kg once every 3 
months has been selected for this study in PH1 patients ≥6 years old with eGF R>45 ≥30 mL/min/1.73 m2.  
Clinical S tudy Protocol ALN -GO1 -003 lumasiran  
Amendment 2 Summary of Changes, 19 March  2019  
 
Alnylam Pharmaceuticals  Confidential  7  Section 3.1, Summary of Study Design  
 Section 3.5, Method of Assigning Patients to Treatment Groups  
Purpose: Update the threshold for the glomerular filtration rate to <30  mL/min/1.73  m2 in the exclusion criteria ; elsewhere state that patients 
included in this study have eGFR ≥30 mL/min/1.73m2. 
The primary change occurs in Section 4.2, Exclusion Criteria #4  
Now reads:  Estimated GFR of ≤45 <30 mL/min/1.73m2 at screening (calculation will be based on the Modification of Diet in Renal 
Disease [MDRD] formula for patients ≥18  years of age and the Schwartz Bedside Formula for patients <18  years of age).  
Sections containing t his change :  
 Synopsis  
 Section1.3, Stud y Design Rationale  
 Section 1.4, Dose Rationale  
Purpose: Delete paragraph to accommodate those site pharmacies whose established policy does not support masking the syringe prior to 
transfer of the study drug from vial to syringe  
The change occurs in 5.2.2, Dose and Administration  
Deleted text:  To maintain the blind, the syringes will be masked prior to study drug withdrawal from the masked vial. A pharmacist, or 
other qualified healthcare professional, will withdraw study drug from the masked vial into the masked syringe.  A full 
description of the blinding procedure is included in the Pharmacy Manual.  
Purpose: Clarify that additional liver function tests are performed when no alternative cause is identified.  
The change occurs in 5.2.3.1, LFT Criteria for Withholding, Monitoring and Stopping Study Drug Dosing (#3)  
Now reads:  For any ALT or AST elevation >3× ULN:  
a. If local laboratory results are obtained, confirm using central laboratory, as soon as possible, ideally within 2 to 3 days, 
but no later than 7 days.  
Clinical S tudy Protocol ALN -GO1 -003 lumasiran  
Amendment 2 Summary of Changes, 19 March  2019  
 
Alnylam Pharmaceuticals  Confidential  8 c. b. If an alternative cause is found, provide appropriate care.  
b. c. If an alternative cause is not found,  perform assessments per Table 6 and Table 9.  
Purpose: Add that  male patients may be required to use contraception (condom) in some countries, such as France, to comply with local 
requirements.  
The change occurs in Section 5.5.1, Contraception  
Now reads:  For male patients, no contraception is required.  However, contraception use by men should be consistent  use by males of 
contraception (condom) may be required in some countries, eg, France, in order to comply  with local regulations  
requirements  as described in the corresponding patient informed consent forms.   
Purpose: Clarify that specific study assessments  may be conducted at a location other than the study center by a home healthcare professional . 
The primary change occurs in 6, Study Assessments  
Now reads:  The schedules of study assessments is provided in Table 1, Table 2, Table 3, and Table 4 .  Study assessments for pregnancy 
test (urine or serum), clinical lab assessments, urine collection, and DNA testing may be conducted at a location other 
than the study center by a home healthcare professional, where applicable country and local regulations and 
infrastructure allow.  
Purpose: Add that patients may be rescreened per investigator judgment and after consultation with the Medical Monitor . 
The primary change occurs in 6.1.2, Rescreening  
Now reads:  A patient who does not meet all study eligibility criteria due to a transient condition observed at Screening (eg, prohibited 
medications that were subsequently discontinued) will  may be allowed to return for rescreening if appropriate in the 
opinion of th e investigator and after consultation with the Medical Monitor .  A patient will be re -consented and assent 
obtained (if applicable) if rescreening occurs outside of the 60 -day screening window.  In this case, all screening procedures 
must be repeated.  
Purpose: Specif y that pregnancy tes ts may be performed more frequent ly per local requirements . 
Clinical S tudy Protocol ALN -GO1 -003 lumasiran  
Amendment 2 Summary of Changes, 19 March  2019  
 
Alnylam Pharmaceuticals  Confidential  9 The primary change occurs in 6.5.6.2, Pregnancy Testing  
Section n ow 
reads:  A serum pregnancy test will be performed at Screening or upon initiation of menarche, if applicable, and urine pregnancy test s 
will be performed thereafter per the Schedules of Assessments and any time pregnancy is suspected.  More frequent 
pregnancy testi ng may be performed where required per local regulations  requirements .   
Sections also containing this change:  
 Table 1, Schedule of Assessments – 6-Month Double -Blind Treatment Period and Blinded Treatment Extension (Screening through 
Month 9 Assessments ) 
 Table 2, Schedule of Assessments – Open Label Extension Period (After Month 9 through Year 5)  
Purpose: Clarify that if the relationship between an AE and the study drug is at least reasonably possible, it is considered “related” to the 
study drug . 
The change occurs in Section 6.5.7.1 Definitions, Relationship of the Adverse Event to Study Drug  
Now reads:  The relationship of each AE to study drug should be evaluated by the Investigator by a “yes” or “no” response to the question : 
“Is there a reasonable possibility that the event may have been caused by the study drug?” A “yes” response indicates that 
the ev ent is considered as related to the study drug.  
Purpose: Update the description of the quality of life questionnaire . 
The change occurs in 6.7,  Quality of Life  
Now reads:  QOL assessments include the following:  
 Kidney disease Quality of Life Questionnaire (KDQOL), specifically the KDQOL SF1.3 and  KDQOL -36 for patients 
≥18 years of age at screening, and the Pediatric Quality of Life Inventory (PedsQL), including the generic and ESRD 
modules  (parent and/or self -report versions) [20] for patients <18 years of age at screening.  
 EQ-5D, a standardized instrument consisting of a questionnaire and a visual analog scale pertaining to 5 dimensions 
(mobility, self -care, usual activities, pain/discomfort, and anxiety/depressi on).  Scoring of the questionnaire is based on 
3 degrees of disability (severe, moderate, or none) .  Scoring of the visual analog scale is based on a visual scale ranging 
from 0 (worst imaginable health state) to 100 (best imaginable health state).  Higher  scores indicate better health status.  
Clinical S tudy Protocol ALN -GO1 -003 lumasiran  
Amendment 2 Summary of Changes, 19 March  2019  
 
Alnylam Pharmaceuticals  Confidential  10 The EQ-5D-5L value set  questionnaire  will be utilized in patients ≥18 years of age at screening, and the 5Y EQ-5D-Y 
questionnaire  value set  will be utilized in patients <18 years of age at screening , where available .[21] 
Purpose: Update the description of the analysis populations.  
The change occurs in 7.2.1, Populations to be Analyzed  
Now reads:   Per-protocol (PP) Set: All randomized patients who received any amount of study drug, had baseline and at least one 
post-baseline 24 -hour urinary oxalate, and did not experience any major protocol deviations that may impact the efficacy 
results within the 6-month double -blinded period.  Patients will be analyzed according to the randomized treatment 
actually recived  arms.  
 All Lumasiran Treated Set: All patients who received any amount of lumasiran including patients who took 
lumasiran during the 6 -month dou ble-blinded period and patients who initially took placebo during the 6 -month 
double -blinded period and then switched to lumasiran during the extension period.  
The primary population used to evaluate efficacy will be the Full Analysis Set . The  for the  primary endpoint will also be 
analyzed for the Per protocol Set and secondary endpoints during the double -blind period .  Safety during the double -
blind period  will be analyzed using the Safety Analysis Set.  The PK Aanalysis  Set will be used to evaluate t he PK 
endpoints.  The All Lumasiran Treated Set will be conducted in the PK Analysis Set used to summarize the long -term 
efficacy and safety of lumasiran . 
Purpose: Update how missing data are handled.  
The change occurs in 7.2.3, Handling of Missing Data  
Deleted text:  To assess the impact of missing data under more conservative assumptions, a pattern mixture model (PMM) based on missing 
not at random (MNAR) assumptions will be performed as a sensitivity analysis.  
Purpose: Update the description of the primary endpoint.  
The change occurs in 7.2.5 .1, Primary Endpoint  
Now reads:  The primary endpoint is to compare the percent change from baseline  to Month 6 in 24 -hour urinary oxalate corrected for 
BSA between the treatment groups in the Full Analysis Set.  The analysis will be performed using a mixed -effect model for  
Clinical S tudy Protocol ALN -GO1 -003 lumasiran  
Amendment 2 Summary of Changes, 19 March  2019  
 
Alnylam Pharmaceuticals  Confidential  11 repeated measures (MMRM) approach.  The outcome variable is percent change from base line in urinary oxalate corrected for 
BSA.  The model includes baseline value as covariate and fixed effect terms including treatment arm and visit (Months 1, 2, 3, 
4, 5, 6).   The treatment estimates from this model will represent an average percent change  from baseline of 24 -hour 
urinary oxalate excretion across months 3 through 6 at which the treatment effect is expected to have reached steady 
state.  Furthermore, given the variability of 24 -hour urinary oxalate, averaging the values across these visits w ill yield 
stable treatment estimates.  
Baseline and Month  6 urinary oxalate values are planned to be collected in triplicate (minimum requirement of duplicate) and 
the calculated mean median of valid collections during each time period (visit) will be used in the analysis. BSA will be 
calculated using the Mosteller formula.  
Purpose: Update the description of the secondary endpoin t analyses . 
The primary change occurs in 7.2.5 .2, Secondary Endpoints  
Now reads:  To control the overall type I error, these  secondary endpoints will be tested in the following hierarchical order:  
• Absolute change in 24 -hour urinary oxalate corrected for BSA from baseline to Month 6  
• Change in 24 -hour urinary oxalate:creatinine ratio (value/ULN) from baseline to Month 6  
• Proportion of patients with 24 -hour urinary oxalate level at or  below 1.5xULN [ULN=0.46 mmol/24h/1.73m2] at Month  6 
• Proportion of patients with 24 -hour urinary oxalate level at or  below ULN [ULN=0.46 mmol/24h/1.73m2] at Month 6  
• Percent change in plasma oxalate from baseline to Month 6  
• Absolute change in plasma oxalate from baseline to Month 6  
Continuous endpoints will be analyzed using an MMRM approach similar to the one described for the primary endpoint.  For 
bBinary endpoints , will be analyzed using t he Cochran -Mantel -Haenszel test stratified by baseline urinary oxalate.  The  
odds ratio and the differences in proportions with corresponding 95% confidence will also be summarized.  
Change in eGFR from baseline to Month  Secondary endpoints assessed beyond Month 6 will be summarized descriptively. 
Change in eGFR over time will also be summarized descriptively.  
Purpose: Update the description of the pharmacodynamic analysis . 
Clinical S tudy Protocol ALN -GO1 -003 lumasiran  
Amendment 2 Summary of Changes, 19 March  2019  
 
Alnylam Pharmaceuticals  Confidential  12 The change occurs in 7.2.6, Pharmacodynamic Analysis  
Now reads:  Urinary oxalate and glycolate excretion, urinary oxalate: creatinine ratio, and plasma levels of oxalate and glycolate 
will be summarized over time descriptively by treatment arm.  Analysis of the PD parameters are specified in 
Section 7.2.5.2. Any PD parameters not alread y prespecified for testing will be summarized descriptively.  
Purpose: Stipulate discontinuation criteria for the termination of the clinical trial or a clinical study site.  
The change occurs in Section 8.1.6, Termination of the Clinical Study or Site Closure  
Now reads:  The Sponsor , or designee,  reserves the right to terminate the study for or a clinical or administrative reasons study site  at any 
time.  If the site does  Conditions that may warrant this action may include, but are  not recruit at a reasonable rate, or if 
there is insufficient adherence  limited  to: 
 The discovery of an unexpected, serious, or unacceptable risk to patients participating in the study  
 Failure of the Investigator to comply with  the protocol , the requirements, the study may  be closed at that site . of the 
IRB/IEC or local health authorities, the Sponsor's procedures, or GCP guidelines  
 Inadequate recruitment of participants by the Investigator  
 The decision on the part of the Sponsor to suspend or discontinue treatment with the  study drug  
Should the study be terminated, and/or the site closed for whatever reason, all documentation and study drug pertaining to th e 
study must be returned to the Sponsor or its representative, and the Investigators, IRB/ IEC/IRB  and Regulatory Authorities 
will be promptly informed of the termination and the reason for the decision.  The Investigator should promptly inform the 
patients and assure appropriate therapy and follow -up. 
Purpose: Remove that an Institution or Investigator must wait 18 months to submit a publication once the primary manuscript has been 
published since the number of months varies per local requirements and this information is specified in the clinical trial ag reement .  
The change occurs in Secti on 8.3, Publication Policy  
Deleted text:  A separate publication by Institution or Investigator may not be submitted for publication until after this primary manuscrip t is 
published, or following the period of 18 months after completion of the study at all  centers . 
Clinical S tudy Protocol ALN -GO1 -003 lumasiran  
Amendment 2 Summary of Changes, 19 March  2019  
 
Alnylam Pharmaceuticals  Confidential  13 Purpose: Correct typographical errors, punctuation, grammar, abbreviations, and formatting.  
These changes are not listed individually.  
 
Clinical S tudy Protocol ALN -GO1 -003 ALN -GO1 (lumasiran ) 
Amendment 1 Summary of Changes , 23 July 2018  
 
Alnylam Pharmaceuticals  Confidential  1 ALN -GO1 -003 PROTOCOL AMENDMENT 1   
SUMMARY OF CHANGES DATED  23 July 2018  
 
ILLUMINATE -A:  A Phase 3 Randomized, Double -Blind, Placebo -Controlled Study with 
an Extended Dosing Period to Evaluate the Efficacy and Safety of Lumasiran in Children 
and Adults with Primary Hyperoxaluria Type 1  
 
Rationale for Protocol Amendment  
The primary purpose for this protocol amendment is to provide additional clarification  about the 
patient caregiver surv eys specific to patients under the legal age of consent, and to make 
corrections to  the Open Label Extension Period Schedule of Assessments, which was missing  the 
Month 27  visit in Year 2  (Study Day 757 ±14 days) .  In addition, t he visit schedule for the 
12-lead electrocardiogram and renal ultrasound assessments through Year 5 in the Open Label 
Extension Period was corrected  from  annually to Month 36 and Month 48.  
In the clinical laboratory assessments table, a correction was made to remove the 
immunogenic ity (antidrug antibodies) assessment from the table , which was erroneously 
included in the original table . 
Also, the nomenclature used in the protocol title was updated.  
A detailed summary of changes is provided in  Table  1.  Corrections to typographical errors, 
punctuation, grammar, abbreviations, and formatting  (including administrative changes between 
the original protocol  and amendment 1 ) are not detai led. 
 
Clinical S tudy Protocol ALN -GO1 -003 ALN -GO1 (lumasiran ) 
Amendment 1 Summary of Changes , 23 July 2018  
 
Alnylam Pharmaceuticals  Confidential  2 Table  1: Protocol Amendment 1 Detailed Summary of Changes  
The primary section(s) of the protocol affected by the changes in Protocol A mendment 1 are indicated.  The corresponding text has 
been revised throughout the protocol.  Deleted text is indicated by strikeout ; added text is indi cated by bold  font. 
Purpose:  Updated nomenclature used in the protocol title 
The primary change occurs in the title page  
Revised title:  ILLUMINATE A003:  A Phase 3 Randomized, Double -Blind, Placebo -Controlled Study with an Extended Dosing Period 
to Evaluate the Efficacy and Safety of Lumasiran in Children and Adults with Primary Hyperoxaluria Type 1  
Section(s) also containing this change:   
 Synopsis  
Purpose:  Added Month 27 visit to the Open Label Extension Period Sch edule of Assessments, and corrected  scheduled visit s for 12 -lead ECG and 
renal ultrasound assessments  from annually to Month 36 and Month 48.  
The primary change occurs in Table 2:  Schedule of Assessments – Open Label Extension Period (After Month 9 through Year 5)  
Purpose:  Upda ted patient and caregiver experience survey information  
The primary change occurs in Section 6.8, Patient and Caregiver Experience Surveys  
Clinical S tudy Protocol ALN -GO1 -003 ALN -GO1 (lumasiran ) 
Amendment 1 Summary of Changes , 23 July 2018  
 
Alnylam Pharmaceuticals  Confidential  3 Revised text : The patient and caregiver experience survey s assess es patients’ experience living with PH1, including their experience 
with PH1 treatments, as well as the effect of PH1 on patients’ caregivers.  Th eseis survey s will be completed at the time 
points specified in the Schedules of Assessment ( Table 1 and Table 2 ) and each  takes approximately 10 minutes to 
complete.  
For the Patient Experience Survey , patient portion of the experience survey , patients ≥1 38 years of age at screening will 
complete the survey themselves if they are able.  If the patient is unable to complete the Patient Experience Survey  
survey  alone, their caregiver or site staff may complete the survey for the patient.  If the patient is <1 38 years of age at 
screening, a caregiver will complete the Patient Experience Survey on behalf of the patient for as long as the patient 
remains under the legal age of consent the patient section of the survey on behalf of the patient for as long as the patient 
remains <18 years of age .   For patients who reach the legal age of consent per local regulations 18 year s of age during the 
study, caregivers will be encouraged to continue completing the patient section of the survey,  but are not required to do 
so.  Additionally, for patients under legal age of consent at the time of screening, their caregiver will also be  asked 
to complete the Caregiver Experience Survey. For patients who reach the legal age of consent per local regulations 
during the study, caregivers will be encouraged to continue completing the survey, but are not required to do so .   
For the Caregiver Experience Survey, caregivers will be asked to complete the survey at all time points  
Section(s ) also containing this change:  
 Section 6.9, Patient and Caregiver Impact Questionnaire  
Clinical S tudy Protocol ALN -GO1 -003 ALN -GO1 (lumasiran ) 
Amendment 1 Summary of Changes , 23 July 2018  
 
Alnylam Pharmaceuticals  Confidential  4 Purpose:  Updated patient and caregiver impact questionnaire details  
The primary change occurs in Section 6.9, Patient and Caregiver Impact Questionnaire  
Added text:  The patient and caregiver impact questionnaire will be used to assess impacts of PH1 on the patients’ lives, including their 
need to relocate/travel to receiv e treatment, the number and type of healthcare providers they use, and their ability to work 
and/or go to school.  The questionnaire will also assess the impact on caregivers’ employment.  This survey 
questionnaire  will be completed at the time points spec ified in the Schedules of Assessment (Table 1 and Table 2 ) and 
takes approximately 10 -12 minutes to complete.  
Patients ≥1 38 years of age at screening will complete the questionnaire  themselves if they are able.  If the patient is 
unable to complete the s urvey alone, their caregiver or site staff may complete the survey on the patient’s behalf.  If the 
patient is <1 38 years of age at screening, a caregiver will complete the patient section of the  questionnaire on behalf of the 
patient  for as long as the pa tient remains <18 years of age .  For patients who reach the legal age of consent per local 
regulations  18 years of age  during the study, and whose caregivers had previously completed the Patient Impact 
Questionnaire  on their behalf, caregivers will be enc ouraged to continue completing the questionnaire, but are not 
required to do so  
Section(s ) also containing this change:  
 Section 6.8, Patient and Caregiver Experience Surveys  
Purpose:  Correct typographical errors, punctuation, grammar, abbreviations, and formatting  
These changes are not listed individually.  
 